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Abstract 
 
The aim of this study was to investigate the powerful muscle regulator, myostatin, and its 
regulators in response to an acute bout of plyometric training. The participants were recruited and 
screened by characterization by means of isometric force production tests, baseline blood creatine 
kinase levels and VO2 max results. The selected individuals (n=15) were subjected to a baseline 
muscle biopsy for comparative purposes. The study made use of plyometric jumping, as source of 
eccentric exercise, to serve as an exercise intervention after which muscle biopsies (4 hours post 
and 24 hours post) and blood draw (4 hours post, 24 hours post and 48 hours post) samples were 
taken. Maximal voluntary isometric contractions of the knee extensors were also measured 
immediately after the exercise protocol and after 1 week recovery. Creatine kinase (CK) analysis 
on the serum samples was used to conclude muscle damage. The muscle biopsy samples were 
used for protein quantification (Western blot) and gene expression assessment (semi-quantitative 
and real-time PCR). The results showed decreased force production immediately after eccentric 
exercise (p < 0.05), while returning back to baseline values at 1 week post exercise and CK results 
showed a significant increases at 4 hours (p<0.05), 24 hours (p<0.001) and 48 hours (p<0.01) after 
exercise. There were no significant differences in myostatin precursor protein (43 kDa), 
phosphorylated Smad2,3, Smad7 or activin receptor IIb in response to eccentric exercise. 
However, the follistatin protein was increased at both 4 hours and 24 hours after exercise (p<0.01). 
RNA analysis of the extracellular matrix (ECM) protein, decorin, revealed the existence of the 
splice variants A1 and A2 in human skeletal muscle. The RT-PCR analysis (n=4) of these variants 
showed no significant difference when comparing pre- to post-exercise. The decorin core protein 
was also investigated by means of antibody probing and results revealed the need for ABC 
chondroitinase enzyme treatment before immunoblotting of human skeletal muscle samples. The 
results concerning knee extensor force reduction and circulating creatine kinase showed the 
effectiveness of plyometric jumping in producing skeletal muscle damage in the lower limbs of unfit 
individuals, unaccustomed to eccentric exercise. In conclusion, myostatin, and its associated 
signalling cascade, are not activated in early muscle regeneration, but follistatin is increased during 
this phase possibly aiding and initiating the muscle repair process. Future studies: Variants of 
decorin are expressed in human skeletal muscle, increasing the complexity that should be taken 
into account in studies concerning the regulation of decorin in a human model. Investigation into 
myostatin protein at different post-translational levels needs more clarification. Published methods 
and materials used in different laboratories are not consistent and investigators should attempt to 
standardise protocols in order to compare results between studies more effectively. Of importance, 
these results show that the myostatin at protein level report different results compared to mRNA 
analysis and that more investigation into myostatin regulatory factors, with special reference to 
follistatin and decorin, is needed in future human models.   
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Opsomming 
 
Die doel van hierdie studie was om die kragtige spiere reguleerder, miostatin, en sy reguleerders in 
reaksie op 'n akute aanval van pliometriese spronge te ondersoek. Die deelnemers is gewerf en 
gekeur deur karakterisering deur middel van isometriese krag produksie toetse, basislyn bloed 
kreatien kinase vlakke en VO2maks resultate. Die geselekteerde individue (N = 15) is onderhewig 
aan 'n basislyn spierbiopsie vir vergelykende doeleindes. Die studie het gebruik gemaak van 
pliometriese spronge (essentriese spier aksie) as die oefening intervensie waarna spierbiopsie (4 
uur na en 24 uur na) en bloed (4 uur na, 24 uur na en 48 uur na) monsters geneem is. Isometriese 
kontraksies van die knieverlengers is ook gemeet onmiddellik na die oefening protokol en na 1 
week se herstel. Kreatine kinase (KK) ontleding van die serum monsters is gebruik om spierskade 
aftelei. Die spierbiopsie monsters was gebruik vir proteïen kwantifisering (Western klad) en die 
assessering van geen uitdrukking (semi-kwantitatiewe en real-time PCR). Die resultate het gewys 
dat krag produksie afgeneem het onmiddellik na essentriese oefening (p <0.05), terwyl dit 
terugkeer na die oorspronklike waardes 1 week na oefening en KK resultate toon 'n beduidende 
toename by 4 uur (p <0,05), 24 uur (p <0,001) en 48 uur (p <0,01) na oefening. Daar was geen 
betekenisvolle verskille in Miostatien voorloper proteïen (43 kDa), gefosforileerde Smad2,3, Smad7 
of Activin reseptoor IIb in reaksie op essentriese oefening. Dit is egter die follistatien proteïen wat 
verhoog by beide 4 uur en 24 uur na oefening (p <0,01). RNS ontleding van die ekstrasellulêre 
matriks (ESM) proteïen, decorin, het die bestaan van die splitsing variante A1 en A2 in menslike 
skeletspier, aan die lig gebring. Die RT-PCR analise (n = 4) van hierdie variante het geen 
betekenisvolle verskille getoon wanneer voor met na-oefening vergelyk is. Die decorin kern 
proteïen is ook ondersoek deur middel van teenliggaam afhanklike metodes en resultate het die 
behoefte aan ABC chondroitinase ensiem behandeling voor immunokladding van menslike 
skeletspier monsters gesteun. Die resultate aangaande knieverlenger krag vermindering en 
sirkuleerende kreatien kinase het die doeltreffendheid van pliometriese spronge in die 
vervaardiging van skeletspier skade in die onderste ledemate van individue ongewoond aan 
essentriese oefening verseker. Ten slotte, Miostatien, en sy verwante sein kaskade, is nie 
geaktiveer vroeg in spier herstelling, maar follistatien is tydens hierdie fase verhoog en help 
moontlik met die aanvang van die spier herstel. Toekomstige studies: variante van decorin word 
uitgedruk in menslike skeletspier, wat die kompleksiteit aangaande decorin verhoog en dit is iets 
wat in ag geneem moet word in studies wat handel oor die regulering van decorin in mens modelle. 
Ondersoek na miostatien proteïen op verskillende na-translasie vlakke moet meer duidelikheid 
verkry. Gepubliseer metodes en materiaal wat gebruik word in verskillende laboratoriums is nie 
konsekwent en ondersoekbeamptes moet probeer om protokolle te standaardiseer sodat resultate 
van studies meer effektief kan vergelyk word. Van belang is, die resultate wys dat miostatien op 
proteïen vlak verskillende resultate vertoon in vergelyking met boodskapper-RNS ontleding en dat 
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meer ondersoek na miostatien regulerende faktore, met spesiale verwysing na follistatien en 
decorin, nodig is in toekomstige menslike modelle. 
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1 Chapter 1: Introduction 
1.1 Structure of skeletal muscle 
 
The skeletal muscle system is responsible for movement by shortening the sarcomeres and 
producing force. Skeletal muscle accounts for approximately 40% of total body weight in men and 
32% in women thus making it the heaviest organ of the human body. Unlike smooth and cardiac 
muscle cells, skeletal muscle is considered to be striated and voluntary (1).  
Skeletal muscle is made up of a numerous multinucleated muscle fibres, positioned parallel to 
each other, and bundled together by connective tissue.  During embryonic development muscle 
fibres are constructed by the fusion of mononucleated myoblasts. Within each muscle fibre, the 
major structural feature is the existence of multiple myofibrils (see Figure 1.1 for schematic of a 
myofibril). The myofibrils are made up out of thick (myosin) and thin (actin) filaments. When 
myofibrils are investigated with electron microscopy, a parallel pattern of dark (A bands) bands and 
light (I bands) are observed. The A-bands, consist of thick filaments and have a lighter area in the 
middle, known as the H-zone. The M-band runs down the middle of the H-zone in the centre of the 
sarcomere and is important to hold the thick filaments together vertically. The I-band is made up of 
thin filaments and in the middle of the I-bands is a dense line called the Z-disk. The Z-disks are 
known as the borders of the sarcomeres, which are the functional units of skeletal muscle. The Z-
disk plays an important role in structural stability during contraction and links the sarcomeres to 
other elements of the intracellular cytoskeleton e.g. desmin. (1)  
Titin is another important part of the sarcomere structure as it overlaps the Z-disk and M-band of 
the sarcomeres resulting in a continuous elastic filament within the cell (2). Multiple structural 
domains are present in Titin including the I-band domain of titin that is made up of Immunoglobulin-
like (Ig)-domains and PEVK and N2B segments, which affect elasticity and are activated by muscle 
stretching (3–5). Affected titin expression has been found to possibly lead to severe myopathies 
and premature death, emphasizing the important of titin (6,7). 
. 
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1.1.1 Extracellular matrix 
 
Within skeletal muscle, the extracellular matrix (ECM) also plays a crucial role and can be 
subdivided into three sections, namely; the endomysial (around the muscle fibre), perimysial 
(around bundles of muscle fibres) and epimysial (around the whole muscle) connective tissue (8) 
(see Figure 1.2 for schematic). 
 
The ECM is associated with providing supporting scaffolding for the surrounding cells and tissues, 
leading to cell aggregation and also aiding cell migration (9). The ECM is a dynamic entity which is 
continuously modified, degraded and reassembled during states of development, disease and 
homeostasis (9–11).   
 
The muscle ECM consists mostly of collagen, a major structural protein, that makes up 1-10% of 
muscle dry weight (12,13). Several types of collagen have been characterized within the skeletal 
muscle ECM, although fibrillar types I and III  are the most predominant in adult ECM (14,15). Type 
Figure 1.1 Sarcomere structure: Molecular representative of sarcomeres that make up the skeletal muscle. 
[Adapted from http://physiologyonline.physiology.org/content/25/5/304/F1.large.jpg] 
A- band 
I-band I-band 
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I collagen is suggested to be the main collagen type in the perimysium while type III collagen is 
evenly distributed between the endomysium and epimysium (15).  
The ECM also contains an abundance of factors such as proteoglycans and glycosaminoglycans. 
Most of the proteoglycans in the muscle ECM are part of the small leucine-rich proteoglycans 
family (SLRPs) (16). This SLRP family has a core protein to which GAG (glycosaminoglycan) 
chains are attached. GAG chains consist of long linear carbohydrate polymers and examples of 
SLRP family members are decorin, biglycan, fibromodulin and lumican (17). Proteoglycans, more 
particularly, the negatively charged GAG chains, have the ability to regulate the bioavailability of 
some of the growth factors in the ECM surrounding the muscle (18,19). The ECM also contains 
enzymes like matrix metalloproteinases (MMP) that are able to cleave GAG chains, resulting in the 
release of growth factors such as fibroblast growth factor (FGF)(20) and transforming growth 
factor-β1 (TGF-β1)(21), to name but few. This enables them to be “free” and bind to their 
respective receptors to initiate signalling cascades (20–22). 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2 Contracting muscle 
 
Muscle contraction is initiated with an electrical signal leading to the release of acetylcholine (ACh) 
from the motorneurons onto the muscle fibres. The binding of the ACh changes the membrane 
permeability, resulting in an action potential that is conducted over the surface of the muscle 
membrane. The electrical signal is then relayed within the muscle, travelling to the sarcoplasmic 
reticulum (SR) via the T-tubules. This signal leads to the release of Ca2+ from the lateral sacs of 
the sarcoplasmic reticulum. The increased Ca2+ is crucial for muscle contraction as it enables 
cross-bridge cycling, by binding to troponin and displacing the tropomyosin on the actin, allowing 
Figure 1.2 Basic structure of the skeletal muscle bundles: illustrating the bundle configuration of skeletal muscle and the 
role of the endomysium, perimysium and epimysium to support the structure of the muscle. [Adapted from 
http://training.seer.cancer.gov/anatomy] 
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actin binding to myosin. During concentric contraction actin-myosin cross-bridge cycling results in 
sarcomere shortening leading to whole muscle shortening. (1)  
1.1.3 Eccentric exercise induced skeletal muscle damage 
 
Eccentric exercise, whereby the muscle actively produces force during lengthening, has been 
shown to produce a certain amount of muscle damage (23). It has been suggested that the 
exercise induced muscle damage is initiated by mechanical factors, which include: number of 
contractions, force, specific force and the velocity of the contraction. Greater muscle damage was 
found as the number of eccentric movements increased (24). Lieber and Friden (25) found that 
muscle strain during the lengthening contraction has a larger effect on exercise induced muscle 
damage than high forces. Furthermore, the lengthening velocity was concluded to be an important 
factor in increased muscle damage. These studies supported a mechanical initiation of exercise 
induced muscle damage. 
When looking more closely at muscle mechanism during eccentric contraction, it has been shown 
that higher levels of force are produced while fewer motor units are activated, leading to the 
increased tension within the sarcomeres (26). This may lead to the disruption of myofilaments 
within the stretched sarcomeres. The augmented tension affects especially the Z-disk area (39), 
leading to disruption of the sarcomeres particularly at the Z-disk regions (23,28–30). The 
detrimental effects on the Z-disks lead to damaged cytoskeletal proteins that are normally vital in 
the maintenance of sarcomere structure (31). Furthermore, when the eccentric contraction is 
repetitive with increased intensity, the tension is augmented and may be expanded to the adjacent 
sarcomeres, resulting in a decrease in the amount of intact sarcomeres (32).  
There are many factors contributing to the muscle damage, including the activation of ion channels 
leading to the increase of intracellular calcium levels resulting in the activation of calpains (33). 
These calcium-activated proteases cleave important structural proteins including titin, desmin, 
troponin and tropomyosin (33).The damaged muscle also initiates an inflammatory process, with 
increases in macrophages and neutrophils within the muscle (34).  
Nonetheless, the mechanical stress placed on the muscle during the lengthening contraction 
seems to be the initial incident leading to subsequent events which end up with the damaging of 
intracellular proteins, decrease in force and increased muscle soreness, which peaks at 24-72 
hours after exercise (35,36). The muscle soreness, more commonly known as DOMS (delayed 
onset of muscle soreness), is not correlated with the magnitude of the muscle damage induced by 
the exercise (37). Release of various muscle proteins into the circulation also do not correlate 
directly with the magnitude of damage. However, both these variables may be used as an indirect 
indication that damage has occurred, irrespectively of the amount. 
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1.1.4 Indirect muscle damage indicator - creatine kinase 
 
Creatine kinase (CK) is an enzyme with a molecular weight of approximately 82 kDa and is found 
in the cytoplasm and mitochondria of cells with a high energy demand such as skeletal muscle. 
The muscle specific creatine kinase consists of two identical sub-units, also known as the muscle 
type subunits (M) forming a primary MM enzyme. The mitochondrial creatine kinase found in 
skeletal muscle is known as the Mt-CK (38). The function of creatine kinase relates to the 
reversible phosphorylation of creatine (39).  
 
Once creatine is phosphorylated by creatine kinase, the phosphocreatine then transfers a high 
energy phosphate group to ADP to form cellular energy unit ATP (40,41).   
 
 
 
This emphasizes the importance of creatine kinase in producing energy and forming the core of the 
phosphocreatine energy system.  
 
In the case of eccentric exercise, skeletal muscle is exposed to unaccustomed muscle action 
which leads to variable degree of mechanical muscle damage (42). The accompanying metabolic 
disturbance is the possible cause of the released cellular components, occurring in a sequence: 
First a reduction of ATP and the reduced uptake of extracellular calcium into the sarcoplasmic 
reticulum due to the dysfunction of associated SR membrane ATPase; this is followed by the 
increase and activation of intracellular proteolytic enzymes leading to the increased degradation of 
muscle proteins, resulting in increased leakage of cellular components (43,44) (see Figure 1.3). In 
healthy individuals exposed to isolated mild to moderate damage it was shown that the clearing of 
circulating muscle components occurs within 7-9 days (45,46). 
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The same exercise protocol may lead to different levels of creatine kinase in the blood, even in a 
group of subjects with similar age, gender, and training status. In many cases, the reason for this is 
unknown, although in some cases it is possibly an effect of muscle pathology like myopathy or and 
cardiomyopathies (47–50).  
 
The baseline serum CK levels in the general population varies from between 35 - 176 U/L (51), but 
in the examples of individuals suffering from rhabdomyolysis, CK can be between 10,000 – 20, 000 
U/L and can achieve levels as high as 3 x 106 U/L (52). This abnormally high level of CK indicates 
a strong disturbance of striated muscle, leading to this increased efflux of intracellular muscle 
components. As a guideline, it is suggested that serum CK levels higher than 5,000 U/L occurring 
in the absence of myocardial or brain infarction, physical trauma or disease, serves as an 
indication of serious muscle disturbance (44).  
1.1.5 Connective tissue damage associated with eccentric muscle action 
 
Aside from the commonly discussed muscle damage associated with eccentric exercise, there is 
also the aspect of connective tissue damage accompanying this mode of exercise (53). A study 
using an animal model showed an increase in collagen content when rats were exposed to 4 
weeks of lengthening contractions (54). This may be part of the adaptation following eccentric 
Unaccustomed exercise – eccentric exercise 
(plyometric jumps)
Mechanical muscle damage
Reduction of ATP
Sarcoplasmic reticulum (SR) disturbance –
reduced Ca2+ uptake 
Activation of proteolytic enzymes –
degradation of muscle proteins
• Leakage of cellular components – e.g creatine kinase
Figure 1.3 The sequence of events leading to the increase in serum creatine kinase observed after exercise 
induced muscle damage 
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exercise, as it was demonstrated that increased connective tissue is linked with a decreased injury 
response to subsequent lengthening contractions (55).  
The direct investigation of connective tissue damage in human subjects is limited; however indirect 
methods are used to evaluate the damage. One of the indirect markers that has been used is 
hydroxyproline, and a study investigating Navy Seals during an intense physical training program 
showed elevated levels of hydroxyproline associated with activity induced connective tissue 
damage (56). In contrast, concentric exercise did not result in changes in serum hydroxyproline 
(57). Aside from the hydroxylated-amino acids, elevated pyridinoline levels in the urine after 
eccentric exercise, are also associated with collagen breakdown (53).  
A study by Brown et al. (53) investigated the differences in response to maximal force production 
and different indirect markers of damage in response to a bout of concentric exercise followed by a 
bout of eccentric exercise. The results showed a significant increase in the CK and lactate 
dehydrogenase isoenzyme (LDH-1) levels after the eccentric exercise. There were no changes in 
serum hydroxyproline, but increased levels of collagen were observed on days 1 and 9 after 
exercise. The maximal voluntary isometric contraction force (MVC) of the subjects was also 
affected and testing showed decreased MVC immediately after the eccentric contractions (42).  
1.1.6 Force production following exercise induced muscle damage 
 
Eccentric contractions are responsible for a decrease in force production due to the increased 
muscle damage associated with lengthening contraction (58,59). The lengthening contractions 
overstretch the sarcomeres leading to reduced contractile protein cross bridge interaction (60) as 
well as excitation-contraction coupling (61), subsequently resulting in decreased strength. Maximal 
voluntary contraction (MVC) during isometric contractions is commonly used to assess strength 
after eccentric exercise and is considered a good tool for indication of damage (62). During testing, 
isometric contractions are held for 2-5 seconds at a set angle. This method has been used for 
testing force production in elbow flexors and knee flexors after eccentric exercise (63), however it 
seems that the elbow flexors (63) are more affected by damage compared to the lower limbs (64). 
This is evident in the 50-60% (63,65,66) strength reduction in elbow flexors compared to around 
35% (67–69) in knee flexors following exercise. In more intense eccentric protocols 50-70% 
reduction in strength were reported, with recovery time possibly spanning over several weeks (70). 
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1.2 Skeletal muscle responses: regeneration and adaptation 
 
Skeletal muscle responses to damage include both regeneration and adaptation. Repair is a 
complex interplay of molecular factors and successful repair is dependent on the synchronization 
of inflammation and regeneration (71,72). Muscle repair consists of two phases: degeneration and 
regeneration. These two phases are dependent on each other. The sequence for muscle repair 
remains the same, but can be affected by the cause of the damage, kinetics of each phase, 
magnitude of the damage and the damage model used (71,73–76). When damage is induced by 
exercise, exercise-induced adaptations may also be stimulated to reduce the likelihood of damage 
if the same insult was experienced again in the future (77–79).  A lot of attention has been paid to 
the mechanisms of repair following eccentric exercise (80,81), but less attention has been paid to 
the stimuli for adaptation. This is complicated by the fact that some molecular responses are most 
likely common to both processes. 
The most important aspects of muscle repair are the activation, proliferation and differentiation of 
cells aiding in the rebuilding process. This introduces the role of satellite cells and their myogenic 
regulatory factors in muscle regeneration. 
1.2.1 Satellite cells and myogenic regulatory factors in regeneration 
 
Satellite cells are a small population of muscle precursor cells discovered by Mauro in 1961 (82) 
and they give skeletal muscle the ability to adapt and regenerate after damage. In the absence of 
muscle damage, these satellite cells remain quiescent in their niche between the basal lamina and 
sarcolemma (83). In the instance of myotrauma, satellite cells are activated and proliferate 
increasing their numbers and start expressing myogenic markers. These activated satellite cells, 
also known as myoblasts, can then fuse with existing muscle fibres or form new myofibres, 
subsequently aiding in the muscle regeneration process (84,85).  
The satellite cells in intact muscle are mainly in a state of mitotic quiescence (G0). These quiescent 
cells are commonly characterized by being Pax7+/MyoD-/Myogenin- (86). In the presence of 
damage, these satellite cells are activated and start to proliferate exiting their state of quiescence. 
The activation of satellite cells is controlled by several factors affecting the satellite cell niche and 
signalling pathways. Interestingly, the activation of satellite cells is not only limited to the site of the 
myofibre injury, as satellite cells from different areas of the myofibre can be activated and induced 
to migrate to the site of injury (87). This occurrence is facilitated by the regulation of the anti-
adhesive molecule, sialomucin CD34 (88). In vitro evidence suggest that regulation of Eph 
receptors and ephrin ligands in satellite cells also aid in directing satellite cell migration (89) 
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MyoD is part of the group of the bHLH (basic helix-loop-helix) proteins, which is associated with 
muscle differentiation although its upregulation already occurs during proliferation (90). The MyoD 
gene is considered as an example of a master control gene in the differentiation process (91).  
MyoD has been shown to be capable of fully activating the muscle differentiation program in both 
in vitro and in vivo models (92). MyoD was found to be responsible for promoting gene expression 
of proteins like desmin and myosin heavy chain, even in non-muscle cells (92). It has also been 
found that MyoD has a binding site in the upstream promoter region of the myostatin gene. Since 
myostatin is a muscle-specific anti-growth factor, this suggests a link or regulation system existing 
between MyoD and myostatin that could, together, have powerful regulatory effect on satellite cell 
differentiation (80, 92). This could be independent of the effects on muscle anabolism or atrophy 
(see 1.2.2).   
The other members in this group include Myf5, MRF4 (myogenic regulator factor) and Myogenin. 
During the formation of muscle, Myf5 and MyoD play an important role in the establishment and 
maintenance of the muscle progenitor cells, while MRF4 plays several roles in myogenesis. Lastly, 
Myogenin is important for terminal differentiation. These bHLH proteins consists of four conserved 
domains: 1) a section known as TAD (transcriptional activation domain), making up the amino 
terminal region 2) cysteine/histidine rich region 3) basic-helix-loop-helix region in the middle and 4) 
α-helix domain at the carboxy terminal (93,94). The TAD domain is known to be a potent 
transcriptional activator (95) while the cysteine/histidine (C/H) domain along with the α-helix 
domain are involved in chromatin remodelling, allowing previously repressed muscle specific 
genes to be expressed (94). The bHLH region within these transcriptional factors is important for 
the binding to the E-box consensus sequence, located in the regulation control regions of several 
muscle specific genes (96–98).   
During the process of muscle regeneration, both MyoD and Myogenin play important roles in the 
promotion of muscle specific genes (99–102) leading to differentiation in activated muscle satellite 
cells (see Figure 1.4). These two factors are able to bind to the E-box sequence (CANNTG) in the 
promoter region of muscle specific genes. Studies investigating cultured MyoD -/- myoblasts 
revealed a reduction in myogenic specific gene expression leading to delayed differentiation e.g. 
lower levels of myosin heavy chain, myogenin, MRF4 and acetylcholine receptor- δ (103–105). 
Myogenin is also one of the basic-helix-loop-helix (bHLH) transcription factor which forms part of 
the myogenic regulatory factor (MRF) family (106–111). This MRF family members have the ability 
to regulate expression of each other and other muscle specific muscle proteins (91,112,113). 
 
Other pathways have also been implicated in the activation of satellite cells (114–116) and MRFs 
including several factors e.g. HGF (117), FGF (118), IGF (119,120) and nitric oxide (121). 
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1.2.2 Hypertrophy and Atrophy 
 
The increase in skeletal muscle mass in response to a weight bearing stimulus is associated with 
the increase in signalling through the PI3K/Akt pathway, leading to the downstream activation of 
factors increasing protein synthesis (122,123). Insulin-like growth factor-1 (IGF-1), is one of the 
main contributors to hypertrophy and one of the agents able to induce the activation of the 
PI3K/Akt pathway (122,123). In response to muscle overload, IGF-1 is locally produced and 
initiates the Akt pathway leading to the resulting muscle hypertrophy. The effect of IGF-1 was 
illustrated when mice were genetically modified to overexpress IGF-1, showing a dramatic increase 
in myofiber hypertrophy (124).  Studies in Drosophila aided in constructing the map for the Akt 
pathway and revealed that IRS-1 (125), P13K (126), mTOR (127) and p70S6K are important for 
skeletal mass and without any of these factors there is a decrease in cell size. Regulation of cell 
size is therefore controlled by signalling pathway responses to mechanical loading or growth 
factors, or both.     
 
 
 
 
 
 
 
Figure 1.5 Schematic of the signalling involved in hypertrophy and atrophy within skeletal muscle 
Figure 1.4 Myogenic pathway: illustrating the progression of satellite cells to myotubes and illustrating the stages at 
which myogenic transcription factors are involved. [Adapted from Langley et al. (81)] 
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In the instance of IGF-1, mTOR is activated downstream of Akt, however, it has been found that 
the amino acid Leucine directly increases mTOR signalling and subsequently augments protein 
synthesis (128).  
It seems that mTOR serves as a master regulator of the pathway and integrates a variety of 
signals, affecting protein synthesis. Proof of its central role has been provided in vitro. The 
inhibition of mTOR, by a pharmacological agent in cell culture, inhibited the activation of p70S6K 
which attenuated the anabolic outcome of Akt or IGF-1 (123,129,130)(see Figure 1.5).  
Studies have provided evidence that exercise induced muscle damage enhances IGF-1 production 
leading to an anabolic response (either repair or hypertrophic) associated with the exercise. A 
study by Bamman et al. (131) revealed that although concentric exercise does not lead to a 
significant change in IGF-1 or IGF-binding protein-4 (IGFBP4) mRNA levels, the opposite is true for 
eccentric exercise. However, IGF-1 mRNA was significantly increased in response to eccentric 
exercise while IGFBP4 was significantly decreased, suggesting the link between muscle damage 
(prominent with eccentric exercise) and IGF-1 response (131). Furthermore, all three isoforms of 
IGF-1 (IGF-1Ea, IGF-1Eb and IGF-1Ec, also known as Mechano Growth Factor (MGF)) were 
investigated by McKay et al. (132) in an in vivo setting. The study used eight healthy male subjects 
to perform 300 knee extensors lengthening contractions. Analysis revealed that MGF mRNA were 
significantly increased at 24 hours after the exercise protocol while the other two isoforms exhibited 
no increase until 72 hours post exercise (132). The timing of MGF expression post exercise, 
suggests that MGF plays an important role in the repair process in response to exercise induced 
muscle damage. 
The inhibition of glycogen synthase kinase 3-beta (GSK3β) by Akt is an additional method in which 
hypertrophy is increased, as the expression of inactive GSK-3β resulted in skeletal myotubes 
hypertrophy (123,133). Interestingly, by decreasing the activity of GSK3β, there is higher activity of 
translational initiation factor eIF2B (134) which suggests that protein synthesis can be upregulated 
without the activation of mTOR (see Figure 1.5). This was supported in models using Wnt1, a 
known inhibitor of GSK3β (135). Members of the Wnt family are also known to play a role in 
satellite cell regulation, possibly providing for integration between muscle fibre hypertrophy and 
satellite cell activation/fusion (136–138).   
Aside from the ability of Akt to initiate the anabolic signalling leading to protein synthesis, it also 
decreases signalling through the atrophy pathways responsible for protein breakdown. In vitro 
studies using dexamethasone to induce atrophy have shown that upregulated MAFbx and MuRF1 
could be antagonized by IGF-1 treatment, also initiating the P13K/Akt pathway (139–141). Muscle 
size is dependent on the balance between pro- and anti-anabolic signals induced by pro-growth or 
anti-growth factors, respectively. The interconnection is complex. For example, the downregulation 
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of MuRF 1 and MAFbx is dependent on the effect of Akt on FoxO transcription factors which 
regulate expression of these ubiquitin ligases. When FoxO is phosphorylated by Akt it is excluded 
from the nucleus (140).  
1.3 Significant roles of Myostatin in skeletal muscle 
1.3.1 Myostatin/ Growth differentiation factor-8 (GDF-8) 
 
Myostatin, a well-known negative regulator of muscle mass, was first reported in 1997 in research 
by McPherron et al. (142) in a study in which the myostatin null mice, resulted in 2-3 times larger 
muscles compared to the wild type mice. Following the original discovery of myostatin, several 
papers were published associating myostatin gene mutations with double-muscled cattle, (143–
146) confirming the powerful effect of myostatin on muscle mass regulation. A prominent study 
described the phenotype of a boy, who at birth, was normal apart from the clear increase in muscle 
mass and 7 months after birth the child had clearly defined, big thigh and calves muscles. At the 
age of 4 years and 6 months, the child had the ability to hold two 3 kg dumbbells with his arms 
horizontally extended. Genome analysis of the boy highlighted the presence of a mutation in the 
myostatin gene that affected the splicing of the mRNA gene and hence the insertion of a premature 
termination codon, thus negatively impacting on the production of functional myostatin (147).  
Conversely, in vitro treatment of C2C12 and L6 skeletal muscle cells with the atrophy-inducing 
agent dexamethasone (a cortisol mimetic) showed an increase in both myostatin mRNA and 
protein levels (148). The study suggested that atrophy associated with glucocorticoids may be due 
to this upregulation of myostatin, as a negative muscle mass regulator (148).  
 
The atrophy caused by myostatin in myotubes is as result of the inhibition of Akt by myostatin-
Smad signalling (149). As mentioned earlier, the inhibition of Akt leads to reduced phosphorylation 
of FoxO (139,140), thereby permitting the translocation of FoxO to the nucleus resulting in the 
upregulation of E3 ligases MuRF1 and MAFbx, which are associated with atrophy (139,140). 
Furthermore, myostatin also affects satellite cells during activation (150) and proliferation 
(151,152). Cell studies have revealed that myostatin halts the progression of the cell cycle at G1 
and G2 phases, due to p21 upregulation by myostatin (see Figure 1.6). Myostatin also decreases 
the concentration of Cdk2, which along with increased p21, leads to hypophosphorylation of 
retinoblastoma protein (Rb). This stops the progression into the S-phase (151). In addition, the 
myostatin-Smad signalling pathway inhibit MyoD and Myogenin in a Smad3 dependant manner, 
leading to altered differentiation of myoblasts (81).  
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These findings initiated interest in the possibility that silencing or inhibiting myostatin may reverse 
or aid individuals suffering from loss of muscle due to illness or genetic mutations. 
1.3.2 Myostatin in human models of atrophy 
 
The increase in myostatin is regularly associated with illness-related muscle wasting or cachexia 
observed in people suffering from acute immunodeficiency syndrome (AIDS)(153), heart failure 
(154–156) and kidney disease (157). The decrease in muscle mass has a major effect on the 
quality of life and has been linked to increased mortality (158). 
In individuals (males) suffering from AIDS, the active mature myostatin protein is increased within 
the serum and skeletal muscle, when compared to healthy males (153). Patients with stage 5 
chronic kidney disease also show significantly higher levels of myostatin expression, while the 
expression of IGF-1 was attenuated, when compared to the control. These factors are two of the 
most powerful regulators of muscle mass and this unfavourable balance towards myostatin 
expression might be the main cause associated with muscle wasting in patients with kidney 
disease (159). 
Not only disease, but disuse of muscle (e.g. bed rest or limb immobilization) also leads to atrophy 
within the skeletal muscle and it has been shown that quantifiable muscle atrophy is evident after 
only 5 days of muscle disuse (160). Furthermore, the same study revealed that muscle myostatin 
mRNA expression doubled in groups exposed to the 5 day- and 14-day leg immobilization and that 
myostatin precursor protein decreased only after 14 days (160).  
The negative effects of myostatin associated with illness and the potential advantages that may be 
gained by athletes if myostatin can be regulated or inhibited has been a massive motivational 
factor for research into myostatin. At the moment the number of human studies is limited since  
animal models are easier to manipulate and in some instances naturally occurring genetic 
mutations (143,161) are evident. 
Figure 1.6 Myogenic progression influenced by myostatin - Illustrating the influence of myostatin on myoblast 
proliferation and differentiation [Adapted from Langley et al.(81)] 
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1.3.3 Human exercise studies investigating myostatin 
 
Investigation into myostatin in humans, show the involvement of myostatin in adaptation to both 
endurance and resistance exercise.  
When myostatin mRNA expression is analysed in physically active men and woman after a single 
bout of 30 min running, it was found that expression was decreased up to 4-fold at 8 h and 12 h 
post exercise (162). Similar decreases were observed in the soleus and vastus lateralis of trained 
men, measured in biopsies 4 h after 45 min running bout at 75% of their VO2 max. (33). Furthermore, 
the study reported no changes at 24 h after exercise (163).These results suggest a consistent 
response observed in both chronic and acute endurance training.  
In the instance of resistance exercise, myostatin mRNA expression is decreased after resistance 
training in males and females, irrespective of age (164). The expression still seems to be 
decreased  as late as 48-72 h after the final bout of near maximal resistance training (164). Similar 
decreases were observed after an acute bout of exercise, resulting in a 44% decrease at mRNA 
level for biopsies taken 24 h after exercise in young and old individuals (males and females)(165).  
In contrast, a study by Willoughby (166), investigated myostatin at mRNA and protein level in 
muscle and also included serum myostatin concentration. This study reported an increase in total 
myostatin measured 15 min after a 6 or 12 week resistance training program. The training protocol 
consisted of training 3/week using three sets of six to eight repetitions at 85-90% 1-RM on lower-
body exercises, whereas CON performed no resistance training (166). In another study, myostatin 
mRNA measured 4 h after a single bout of leg extensions performed by endurance-or resistance 
trained subjects, were found to be unchanged (167). Expression information reported by Hulmi et 
al. (168), showed mRNA levels were not affected 1 h after exercise, but were indeed significantly 
decreased 48 h after the final bout of a 21-week training regime. The results from the latter study 
possibly explain the differences in myostatin expression reported at various time points after 
exercise. It would seem that expression is only affected at a later time point, maybe only as late as 
48 h after exercise.  
When investigating myostatin at the protein level (analysis using Western blotting), it has been 
reported that plasma myostatin concentrations were decreased by 20% after exercising twice a 
day for 10 weeks (169). Similar results were found in a study by Saremi et al. (170), who reported 
a 10% decrease in plasma myostatin (analysis was performed using ELISA) after 12 weeks 
resistance training while supplementing subjects with creatine. Again, controversial results 
pertaining to serum myostatin were reported with Kim et al. (171), who reported no changes at 
protein level after 16 weeks of knee extensor resistance training. The study also revealed a high 
level of variance in serum myostatin levels between untrained individuals (171).  
Stellenbosch University  http://scholar.sun.ac.za
15 
 
Copyright © 2014 Stellenbosch University   All rights reserved  
 
In summary, these studies provide evidence that is somewhat contradictory and emphasizes the 
point that exercise mode, duration of study, time point of sample harvesting and training status all 
have effects on protein expression. Furthermore, analysis of myostatin protein expression is often 
incomplete: somewhat lacking in detailed analysis providing complete information concerning the 
processing and activity status of the myostatin and the activation of targeted signalling pathways. 
1.3.4 Myostatin expression and myostatin propeptide 
 
Physiologically, the expression of myostatin is largely influenced by the FoxO1 transcription factors 
(172). It was found in C2C12 cells that FoxO1 induced expressed of myostatin via its binding site in 
the promoter region of the myostatin gene (172). Furthermore, results from the same study 
revealed the involvement of Smads in the expression of myostatin. Over-expression of the Smad 
transcription factors led to increased myostatin promoter activity (172). 
Myostatin gene expression is followed by translation into a precursor protein consisting of 375 
amino acids (aa), including the signal sequence (23 aa), N-terminal propeptide domain (243 aa) 
and a C-terminal domain (109 aa). The precursor protein is cleaved at two sites to produce an 
active form of myostatin. This occurs in several steps. The furin family of enzymes is responsible 
for the first cleavage, removing the 23 aa signal peptide (173)(see Figure 1.7 Step 1). The next 
cleavage by bone morphogenetic protein-1/tolloid (BMP-1/TLD) occurs at the Arg-Ser-Arg-Arg 
(RSRR, aa 263-266) site separating the N-terminal domain (26-27 kDa) from the C-terminal 
domain (12-13 kDa)(173)(Step 2). Two C-terminal domains form a disulfide-linked dimer (26 kDa). 
Two N-terminal domains/myostatin propeptide binds non-covalently to the dimer, forming an 
inactive (latent) complex (174,175)(Step 3). The BMP-1 enzyme family of metalloproteinases has 
been found to be responsible for cleaving the inactive complex between Arg-75 and Asp-76, 
enabling the active (also called the mature) myostatin to then bind the designated receptor (see 
Figure 1.7, Step 4)(176). – All myostatin protein sizes is in accordance with information from UNIPROT online 
database. 
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The myostatin propeptide has been shown to inhibit the biological activity of myostatin in vitro (see 
Figure 1.9)(174). This occurrence was observed in vivo as well, with results showing that a high 
percentage of mature myostatin in normal mouse and human serum is bound to the propeptide 
(177). Furthermore, a significant increase in muscle mass was seen in normal wild-type mice and 
mice suffering from Duchenne muscular dystrophy when gene delivery of myostatin propeptide 
was administered (178). 
1.3.5 Myostatin designated receptor 
 
It is well known that the members of the TGF-β superfamily initiate signalling by binding to 
serine/threonine kinase receptors (175). The activin IIb receptor (ActRIIb) is a serine/threonine 
kinase receptor and was identified as the primary receptor for myostatin. Lee and McPherron 
showed that expression of a dominant negative form (lacking the kinase domain of the receptor) of 
the ActRIIb led to an increase in muscle mass of 125% when compared to control/non-transgenic 
animals (175). Myostatin binding is specific and saturable (175) and leads to activation of members 
of the Smad signalling pathway.  
 
 
Figure 1.7 Myostatin processing and secretion - Illustrates the processing of myostatin after expression and the 
enzymes involved in releasing the active myostatin that binds to the designated receptor.  
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1.3.6 Signalling - Smad dependent 
 
The human genome encodes for a total of eight Smad proteins (179), with five of them (Smad1, 
Smad2, Smad3, Smad5 and Smad8) acting as substrate proteins for the TGF-β family of 
receptors. These are commonly referred to as receptor-Smads (R-Smads). Smad4, also known as 
the co-Smad, is able to serve as a common partner for all R-Smads (179). Smad6, 7 are known as 
the inhibitors of the pathway by interfering with Smad-receptor or Smad-Smad interactions (179).  
The proteins themselves consist of approximately 500 amino acids and have two globular domains 
separated by a linker region (180). The C-terminal (MH2, homology domain) is conserved in all 
Smad proteins (see Figure 1.8) while the N-terminal (MH1, homology domain) is conserved in all 
Smads proteins excluding Smad6 and Smad7 (see Figure 1.8). The MH1 domain seems to be 
responsible for DNA-binding and is stabilized by a tightly bound zinc atom. The linker region serves 
as a binding target for an array of proteins including Smurf (Smad ubiquitination-related factor), 
phosphorylation sites for several protein kinase and ubiquitinase ligases. In Smad4, the linker site 
is the binding region for proteins, nuclear export signal (NES), affecting its localization (180) (see 
Figure 1.8). 
 
 
 
 
 
 
As mentioned above, in the case of active myostatin, the dimer binds with high affinity to the 
Activin receptor IIB (ActRIIb) (175,181). The ActRIIb receptor consists of a short extracellular 
domain which binds the ligand and then a large intracellular portion possessing the 
serine/threonine kinase domain (182,183). Signalling is initiated when the ligand, like myostatin, 
binds ActRIIb receptor which in turn forms a complex with the Anaplastic lymphoma kinase (ALK) 
receptor 4 or 5 (subtypes of type I receptor). This complex phosphorylates, via the serine/threonine 
kinase domain (184). The serine-threonine kinase subsequently phosphorylates Smad2/3 proteins, 
also known as receptor-regulated Smads. The phosphorylated Smad2/3 is then able to form a 
complex with Smad4 to translocate into the nucleus leading to the repression or upregulation of 
specific genes (See Figure 1.9)(185). 
Figure 1.8 Structures of Smad proteins involved in TGF-β signalling [Adapted from Massagué et al. (165)] 
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1.3.7 Inhibitory Smad 7 
 
Interestingly, myostatin is subject to autoregulation. This occurs via the expression of Smad7, a 
downstream gene target of myostatin/Smad2/3 (186). It was also discovered that overexpression 
of Smad7 led to inhibition of activity at the myostatin promoter site (186). Furthermore, research by 
Nakao et al. (187) found that Smad7 is one of the inhibitory Smad (I-Smad) proteins and is capable 
of reducing signalling through Smad2/3 by interfering with the phosphorylation of these proteins 
(see Figure 1.9)(187). The Smad7 protein also interacts with MyoD and enhances its 
transcriptional activity (188). Taken together, Smad7 plays a major role in differentiation in skeletal 
muscle cells (188).  
1.3.8 Regulation of myostatin 
 
Myostatin is regulated by a variety of proteins/factors at protein level, for example proteins; 
interfere with the binding of myostatin to the receptor or via inhibition of the Smad signalling 
pathway. The main regulatory factors involved include myostatin propeptide (174), follistatin (189), 
Smad7 (186,187), Tcap (telothonin)(190) and more recently decorin (191).  
1.3.8.1 Follistatin 
 
Follistatin (FST) is a multi-domain factor able to bind and regulate members of the TGF-β 
superfamily, particularly Activin A and myostatin (see Figure 1.9)(189). The affinity for Activin A 
and myostatin differs, with Kd values of 1.7 nM and 12.3 nM respectively (192). Follistatin type 
proteins are subdivided into follistatin and follistatin-like 3 (FSTL-3). The two proteins differ from 
each other in their molecular structure, binding characteristics and their affinities for members of 
the TGF-β family.  
 
The follistatin protein contains an N-terminal domain and three FST domains (FS Domains 1-3), 
with a heparin-binding site in FS Domain-1 (189,193). The heparin binding site is involved in 
regulation of myostatin via degradation (194). This occurs as follistatin binds myostatin, which 
increases the affinity for cell surface localized heparin (194). The binding of follistatin with heparin 
facilitates the endocytosis of follistatin-bound ligands (189,193). 
  
The crystal structures of FST proteins in complex with myostatin or closely related activin A, 
showed that follistatin inhibits the action of these ligands by blocking all four receptor-binding sites 
(194–198). The analysis shows that the FS Domain-1 and FS Domain-2 are responsible for 
covering the type II receptor-binding site, while the type I receptor binding site is occupied by the 
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N-domain. There are also interactions between follistatin proteins with the N-domain of one 
molecule interacting with the FS Domain-3 of another (192,194,199,200).   
 
The physiological importance of FST was emphasized with studies in which follistatin was 
overexpressed and showed that myostatin effects were decreased leading to a radical increase in 
muscle mass (175,201). In a study by Gilson et al. (202), transgenic mice were modified to over 
express follistatin. The increase in follistatin protein concentration within the muscle induced 
skeletal muscle hypertrophy, including the activation of satellite cells. The hypertrophy induced by 
follistatin was characterized by the increase in DNA content which reflects the number of 
myonuclei. This study also supported the ability of follistatin to inhibit the effects of activin and 
myostatin, leading to increased hypertrophy. In the same study, γ-irradiation was used to destroy 
satellite cells’ ability to proliferate. The muscles were then treated with follistatin by gene transfer 
and the results showed that follistatin is able to induce hypertrophy through protein synthesis. This 
shows that follistatin can affect muscle mass in a satellite cell independent manner (202). 
 
Furthermore, a study by Lee (203) investigated the influences of other ligands in the absence of 
myostatin. The study used Mstn-/- mice which carried a follistatin transgene. The combination of 
follistatin transgene with myostatin null mice resulted in a quadrupling in muscle mass. These mice 
were double the size of the myostatin-null mice. The muscle mass increase included a 73% 
increase in fibre number and a 117% increase in fibre cross sectional area, compared to the wild 
type mice. These results emphasize the ability of follistatin to regulate other ligands involved in 
muscle mass regulation. (203)  
 
The regulation of follistatin expression is not completely clear. However, a link between IGF-1 and 
follistatin expression has been established in quail (204) and duck (205). In the quail, in ovo 
feeding with IGF-1 significantly altered the follistatin expression levels in the developing muscle 
tissue (204). While in duck embryos, the results showed a similar expression pattern for follistatin, 
under the influence of IGF-1: in ovo IGF-1 administration also resulted in an increase in follistatin 
expression within developing skeletal muscle (205). It is therefore suggested that IGF-1 may be 
one of the factors leading to an increase in follistatin mRNA expression (205). 
 
Studies investigating the response of follistatin mRNA levels to exercise, both concentric and 
eccentric, have reported no significant changes (206,207). In the most significant of these studies, 
young males were recruited (along with older participants, results not discussed here) and were 
subjected to six sets of 12-16 maximal eccentric repetitions of single-leg eccentric knee extension 
on an isokinetic dynamometer (206). Skeletal muscle biopsies were taken before the start of the 
study and then 24 h after the exercise protocol, followed by mRNA analysis revealing no change in 
follistatin expression in young men when subjected to eccentric exercise (206).  
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1.3.8.2 Decorin 
 
Decorin is an important regulating member of the dynamic extracellular matrix and is part of the 
family of small proteoglycans. Decorin binds to several substances in the ECM and  regulates 
collagen fibril formation and stabilization of the collagen network (208,209). Aside from the 
structural effects of decorin, it also plays a regulatory role (interference, regulation or stimulation) in 
a variety of pathways and with specific factors. One of the most prominent effects, fibrosis, may be 
due to the capability of decorin to sequester TGF-β1, thereby decreasing the fibrotic response 
(210,211).  
In 2006, a study by Miura et al. (191) introduced another role for decorin showing its ability to bind 
myostatin (see Figure 1.9), another member of the TGF-β superfamily. The in vitro studies showed 
improved myoblast proliferation in the presence of immobilized decorin, relieving the negative 
effects of myostatin on myogenic cell proliferation (191). 
In a study by Li et al. (212) the in vitro effect of decorin on the differentiation of myoblasts was 
investigated. The study went further and also looked at the in vitro and in vivo behaviour of 
myoblasts transfected with the decorin gene (212).  Of interest to the current project, the over-
expression of decorin was shown to upregulate follistatin, p21 and myogenic transcription factors 
while also down-regulating myostatin. All these effects, along with decorin’s ability to sequester 
TGF-β1, may explain the enhanced myogenic differentiation and decreased fibrosis observed in 
the presence of increased decorin (213–217).    
Further work was done by Kishioka et al. (218), in which the investigators generated a C2C12 
model over-expressing decorin. The results showed that free decorin affected myogenic cells by 
enhancing their proliferation and differentiation through interfering with myostatin signalling. The 
results also indicated that the cells over-expressing decorin showed significantly larger myotubes 
at 96 hours. This was accredited to the fact that myostatin inhibition leads to extended proliferation 
(or delayed cell cycle exit) allowing for more myoblasts to ultimately fuse and differentiate. 
Furthermore, the study also found that over-expression of decorin does not affect myostatin 
expression, but decreases the ability of myostatin to elicit its physiological effects (218). To gain a 
better understanding of the multiple effects of decorin, it is useful to understand its effect in 
biological systems other than muscle.  
In vitro, the expression of decorin has also been investigated in human keratinocytes (cHEK cells) 
and a link was revealed between decorin mRNA expression, pro-inflammatory and proliferative 
cytokines (219). The study revealed that treatment of cHEK cells with IL-1β and TNF-α inhibited 
expression of decorin (219). Furthermore, the addition of TGF-β1 resulted in an 80% decrease in 
decorin expression (219). The latter finding concurs with results from Li and Velleman (220) whom 
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also reported decreased decorin expression in response to TGF-β1 in both the endomysium and 
perimysium within the pectoral major muscle during chicken embryonic development.  
Another study investigating decorin expression and more specifically decorin splice variants, 
reported the existence of two variants in human mesangial cells (HMC)(221). The expression of 
these decorin variants were shown to be affected by different concentrations of glucose. 
Furthermore, the changes in environment dictated the initiation site of the transcript, as decorin 
possesses two promoter sites (P1 and P2). Both these promoter sites are situated upstream of the 
first exon, hence after splicing both transcripts produces the same protein (359 aa)(221). The 
significance of this is likely related to the environmental factors activating gene transcription acting 
through different pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Myostatin pathway including regulatory proteins – Shows the binding of myostatin to the ActivinR IIb on 
the cell membrane and the initiation of the Smad pathway, which are able to inhibit several other factors. The Smad 2/3 
and Smad4 transclocation to the nucleus results in the upregulation of p21. The regulatory proteins affect myostatin at 
different points; with decorin, myostatin propeptide and follistatin being able to influence the binding of myostatin to the 
receptor, while Smad 7 is responsible for intracellular inhibition by affecting the phosphorylation of the R-Smads. 
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1.4 Rationale 
 
Although many studies have reported the myostatin response to exercise (162,165,166,222), 
focusing on endurance and resistance training, these studies did not place a lot of emphasis on the 
regulatory factors that have an influence on myostatin. These are essential factors to take into 
account when investigating myostatin or its signalling pathways since they could make the 
concentration of myostatin alone less relevant.  
The reputation of myostatin as a negative regulator of skeletal muscle is firmly established by 
knock-out models or naturally occurring mutations (143,145). However, the effects of follistatin as a 
positive regulator of muscle mass have also been made very clear in a study over-expressing 
these protein in mice (203). Smad7 is also among the regulators of response to myostatin and has 
been reported to enhance myogenesis (223) and also to participate in the autoregulation of 
myostatin (186). Recently decorin was added to the group of factors with a regulatory role in 
relation to myostatin (191) and follow up research has proved the positive effect that decorin over-
expression has on myoblasts by promoting both proliferation and differentiation (218). 
There are numerous reported data emphasizing the major effects that these myostatin regulatory 
factors can have on skeletal muscle resulting in significant increases in muscle mass, by various 
mechanisms. This calls for the focus to be shifted or spread to include these factors in research 
pertaining to myostatin. Furthermore, the research previously done on these factors are mainly in 
rodent or cell models, as these are easier to manipulate. However since the functions of these 
factors are mostly characterized it is suggested to move on to a more complex and applicable 
model, humans. A list of human studies relating to myostatin and known myostatin interacting 
factors is provided in Tables 1.1 and 1.2. Additional studies such as the ones performed during the 
course of this thesis will enable a better understanding of the natural in vivo responses of skeletal 
muscle to interventions, such as exercise. 
The use of eccentric exercise to investigate muscle regeneration would be the best option, as this 
form of exercise is made up of a stretch-shortening cycle (224,225) which introduces an eccentric 
muscle contraction to the exercise. Eccentric exercise causes disruption of muscle fibres 
(23,29,30); this damage initiates muscle regeneration with activation of satellite cells (226) and 
increased proteins synthesis leading to hypertrophy (227). This would suggest that myostatin 
would be tightly regulated in this period of time during early muscle regeneration, with the 
introduction of follistatin and decorin as direct myostatin regulators (175,191,218). 
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Table 1:1 Summary of human studies investigating myostatin in relation to exercise 
1RM – 1 repetition maximum, RT – Resistance training, AE – Aerobic exercise, MB – Muscle biopsy, BD – 
Blood draw 
 
 
 
(Ref) 
year 
Subjects Sex Exercise protocol 
Sample time 
points 
Results 
(228) 
2007 
Untrained Young 
(27.0 years ± 10.1) 
Exercise group (n=9 
Control group (n=6) 
M 
 Exercise group – 6 sets of 15 reps 
maximal eccentric contractions on 
dynamometer for 6 weeks 
 Control group – no exercise 
 Control MB + BD 1 
week before study 
 MB + BD 3 days 
into study 
 MB + BD 24 h 
after final exercise 
session 
 
↓ MSTN mRNA 
throughout 
study 
compared to 
control 
(229) 
2009 
Young ( 21.5 ± 2.9 y) 
Recreationally active 
(n=13) 
M 
 1st bout: 4 sets of 18-20 reps at 
60-65% 1RM 
 2nd bout: 4 sets of 8-10 reps at 80-
85% 1RM 
 Single leg isotonic extensions 
 MB 30 min, 2 h 
and   6 h post 
 
↓ MSTN mRNA 
post exercise 
 
 
(170) 
2010 
 
Young (23.42±2.2 y) 
3 groups: 
 Control (n=8) 
 Resist. + placebo 
(n=8) 
 Resist. + creatine 
(n=8) 
M 
 3 days per week for 8 weeks 
 Each session, 3 sets of 8-10 reps 
at 60-70% 1 RM whole body 
exercise – bench press, lat pull 
down, bicep curls, leg press, knee 
extensors and knee flexors 
 Serum samples at 
baseline (after 
overnight fast) 
week 4 and week 
8. 
 
RT ↓ serum 
MSTN 
RT + Creatine 
greater ↓ serum 
MSTN 
 
(230) 
2011 
Active young (22 ±1.6y) 
– 3 groups 
Endurance group (n=7) 
Strength group (n=7) 
Control group (n=7) 
 
M 
 
 3/week 12 weeks training 
 Endurance training – running 45 
min with HR of 80% of 
aerobic/anaerobic threshold 
 Strength training – whole body, 3 
sets at 70-80% of 1RM 
 Control 
 MB 3-5 days 
before the start 
and after 
completion of 
training regime 
No sig 
difference 
MSTN mRNA 
for any group 
 
(231) 
2012 
Chronic heart failure 
(n=24) divided into 2 
groups- 
Exercise group (n=12) 
Sedentary group (n=12) 
M 
 Sedentary control group 
 Exercise group – first 3 weeks 
exercise 6/day for 5-20 min cycle 
at 25 W then increase by 25 W 
every 3 min 
 12 weeks training 
 MB at baseline 
and after 12 
weeks exercise 
 BD at baseline 
and after exercise 
protocol 
↓ MSTN mRNA 
and muscle 
protein in 
exercise group 
No sig change 
in serum MSTN 
 
(232) 
2012 
Old ( 67.8 ± 1.0 y) 
(n=20) 
Old  (67.2 ±  1.5 y) 
(n=15) 
M 
F 
 3 sets of 12 reps maximal 
unilateral knee extensions 
 MB at baseline 
and 2 h after 
exercise 
 
↓ MSTN mRNA 
post exercise 
(233) 
2012 
Active young (23 ± 2y) 
(n=9) 
M 
 45 min aerobic one legged cycle 
ergometer followed by 4 x 7 
maximal concentric-eccentric 
knee extensions 6h later – one 
leg AE +RT, other only RT 
 MB at baseline 
and 3 h after RT 
 
↓MSTN mRNA 
in AE +RT 
group 
↓MSTN mRNA 
in RT after 
training 
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Table 1:2 Summary of studies investigating myostatin and factors (follistatin, activin receptor IIB 
(ActRIIb) or Smad7) included in present study, RE – resistance exercise, EE – eccentric exercise, CE – 
concentric exercise, RT – resistance training, MB – Muscle biopsy, BD – Blood draw 
 
 
 
(Ref) 
year 
Subjects Sex Exercise protocol Sample time points Results 
(206) 
2007 
 Young (28 ± 5y) (n=10) 
 
 Old (68 ± 6y) (n=11) 
M 
 Bout maximal single leg 
eccentric knee 
extensions 
 6 sets x 12-16 maximal 
contractions 
 MB at baseline and 
24 hr after exercise 
 
No change MSTN 
mRNA 
No change follistatin 
mRNA 
- In any group 
(168) 
2007 
 Untrained older men 
(62.3 ± 6.3y)(n=22) 
 
 Strength training group 
(n=11) 
 Control group (n=11) 
 
M 
 Single RE bout before 
and after strength 
training period 
 5 sets of 10 reps leg 
press 
 MB at 30 minutes, 1 
hr and 48hr after RE 
bouts 
↓ ActivinRIIB mRNA 
receptor 
↓ MSTN mRNA 
(234) 
2009 
 Older (61.4 ± 4.2y) 
 
 Protein group (n=9) 
 Placebo group (n=9) 
M 
 RE = 5 sets x 10 reps 
leg press 
 
 RE + 15g Whey protein 
(before and after) 
 RE + Placebo 
 
 MB at baseline/rest 
and 1hr and 48 hr 
after RE 
 
↑Follistatin-related 
gene (FLRG) mRNA 
in RE + Whey at 48hr 
post 
↓ MSTN mRNA in RE 
+ placebo at 48hr 
post 
No changes in 
ActivinRIIB mRNA 
(207) 
2010 
 Young (25 ±1 y) 
 Eccentric group (n=6) 
 Concentric group (n=6) F 
 7 sessions 
 Group 1 – Single leg 
maximal eccentric knee 
extensions (EE) 
 Group 2 – single leg 
isokenetic knee 
extensions (CE) 
 8 h after 1st session 
 8 h after 7th session 
 Muscle biopsy 
No change FST or 
MSTN mRNA 
(235) 
2012 
 Young 
  
 Low intensity resistance 
training (20.3 ± 4.2y) 
(n=10) 
 
 Low intensity + blood 
restriction resistance 
training (20 ± 4.5y) 
(n=10) 
 
 High intensity 
resistance training (23.6 
± 6y) (n=9) 
 
M 
 8 weeks, bilateral knee 
extensions 
 
 Low intensity (20% 
1RM)(LI) 
 
 Low intensity + 
restricted blood flow 
using an air cuff 
decreasing blood flow 
by around 50% (LIR)  
 
 High intensity (80% 
1RM)(HI) 
 
 
 MB baseline (1 week 
before start) and MB 
48 h after last session 
 
↓MSTN mRNA in LIR 
and HI 
No changes in 
ActivinR IIB mRNA 
↓ FST related 
proteins mRNA –all 
groups 
↑Smad7 mRNA in 
LIR and HI 
(236) 
2013 
 Old (61.2 ± 4.1 years) 
(n=18) 
 Untrained young (26.0 ± 
4.3 years) (n=21) M 
 21 weeks RT knee 
extensions and leg 
press + upper body 
 
 MB before and 1 
week after the last 
training session 
↑ MSTN mRNA in 
older RT group 
No sig diff in FLRG or 
ActivinRIIB in any 
group 
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1.4.1 Aims 
 
1. To determine the existence of exercise-induced muscle damage by means of functional 
testing and serum analysis 
2. To establish if splice variants of the decorin gene are present in human skeletal muscle 
and to quantify their expression in response to eccentric exercise along with immunoblot 
analysis for the decorin protein. 
3. To quantify proteins involved in the myostatin pathway, including myostatin regulatory 
factors such as follistatin and decorin in response to eccentric exercise. 
4. To quantify changes in expression of Smad proteins involved in myostatin signalling, 
including both the pro-signalling proteins (phosphorylated Smad2/3) and the signalling 
inhibitory proteins (Smad7). 
 
1.4.2 Hypothesis 
 
 Isometric force production will decrease immediately after an acute bout of unaccustomed 
eccentric exercise in subjects with average fitness 
 Myostatin protein concentration will be decreased in the short period after an acute bout of 
plyometric exercise 
 The Smad signalling cascade will not be activated during early stages of regeneration, 
concurring with myostatin concentration changes. 
 Activin IIb membrane bound receptor would decrease in skeletal muscle shortly after 
exercise with lengthening contractions as result of membrane damage 
 Regulatory factors affecting myostatin directly or interfering with the canonical pathway will 
be increased in early muscle regeneration after acute bout of eccentric exercise. 
 Follistatin will be mostly affected by exercise, as it serves to regulate an array of growth 
inhibitory factors which will possible hinder protein synthesis and muscle regeneration 
 Variant transcripts of decorin are present in human skeletal muscle and the expression 
patterns of the variants respond to exercise induced muscle damage 
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2 Chapter 2: Materials and Methods 
 
2.1 Reagents list 
 
Table 2:1 List of reagents used in the laboratory analysis along with the manufacturer and catalogue numbers 
Reagents Manufacturer Cat. number 
2-Mercaptoethanol Sigma-Aldrich, USA M3148 
Acrylamide solution 40% Sigma-Aldrich, USA A4058 
Ammonium persulfate–APS Sigma-Aldrich, USA A3678 
Benzamidine Sigma-Aldrich, USA 135828 
Boric acid Sigma-Aldrich, USA B6768 
Bovine Serum Albumin fraction V – BSA Roche, USA 10735078001 
Bromophenol Blue Sigma-Aldrich, USA 318744 
Chloroform Sigma-Aldrich, USA C2432 
Enhanced chemiluminescence (ECL) – SuperSignal West Pico Pierce – Thermo, USA 34087 
Ethanol Sigma-Aldrich, USA E7023 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, USA E9884 
Glycerol Merck- Calbiochem, USA 356350 
Glycine Sigma-Aldrich, USA G8898 
Isopentane Merck Millipore, USA 106056 
Isopropanol Sigma-Aldrich, USA I9516 
Potassium chloride – KCl Merck- Calbiochem, USA 529552 
Leupeptin Merck- Calbiochem, USA 108976 
Methanol Merck-Millipore, USA 1060095000 
MgCl2– Magnesium chloride Merck- Calbiochem, USA 442611 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich, USA T7024 
Nonidet™ P-40 Sigma-Aldrich, USA 74385 
PMSF- phenylmethylsulfonyl fluoride Sigma-Aldrich, USA P7626 
Ponceau S Sigma-Aldrich, USA P7170 
PUGNAc Sigma-Aldrich, USA A7229 
Sodium acetate Sigma-Aldrich, USA S2889 
Sodium chloride –NaCl Merck- Calbiochem, USA 567441 
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Sodium deoxycholate Sigma-Aldrich, USA 30970 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich, USA L3771 
Sodium fluoride Sigma-Aldrich, USA S7920 
Sodium hydroxide – NaOH Merck- Calbiochem, USA 567530 
Sodium Orthovanadate Merck- Calbiochem, USA 567540 
Sodium phosphate dibasic -Na2HPO4 Sigma-Aldrich, USA S7907 
Soybean trypsin inhibitor (SBTI) Sigma-Aldrich, USA T9128 
Tris-base – Trizma base Sigma-Aldrich, USA 93349 FLUKA 
Triton X-100 Sigma-Aldrich, USA 93443 
Tween 20™ Sigma-Aldrich, USA P7949 
Hydrochloric acid 32% - HCl Merck- Millipore, USA 1003192511 
2.2 Ethics statement 
 
This study was approved by Sub-Committee C of the Research Committee of the University of 
Stellenbosch, ethics reference number: N12/08/051 (Approval letter, Appendix). This ensured that 
the study was conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
2.3 Initial subject recruitment 
 
Healthy adult males (n=25) aged between 20-25 years of age were recruited for this study via the 
use of poster advertisements placed within Stellenbosch university buildings, oral presentations to 
undergraduate students and social media i.e. Facebook (www.facebook.com). Initial selection 
criteria for participants involved the following – 
2.4 Inclusion requirements 
 
 Participants had to be physical active, but only participating in a light exercising regime with 
of frequency of 0-2 exercise sessions per week. The exercise regime which participants 
engaged in must not have included any form of eccentric exercise, for example downhill 
running or jumping squats. 
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2.5 Exclusion parameters 
 
 Individuals which are highly trained elite athletes 
 Individuals suffering from type 1 diabetes 
 Individuals chronically treated by any corticosteroid-containing medication. 
Participants who satisfied the above criteria were then invited to the exercise physiology research 
labs at Stellenbosch University whereby the specific details of the study and requirements of 
participants was provided. Informed consent from participants was then obtained. 
2.6 Study design 
 
From the initial recruitment of 25 subjects, only 15 were chosen to continue. Participants visited the 
exercise physiology laboratory at Stellenbosch University on 10 separate occasions over the 
course of (8 weeks) in order for all physiological measurements to be taken. A schematic of what 
each of the ten visits entailed is provided in Figure 2.1 while a detailed description of protocols 
used in collection of tissue and blood samples is provided below. 
Figure 2.1 Time line scheme of the research trial 
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Visit 1 – Height, weight and blood pressure measurements were obtained for each participant. A 
blood sample was also obtained that would provide information on the baseline levels of creatine 
kinase for each participant. The protocol for each blood draw was as follows: 
 Participants were placed in a supine position 
 An 21 gauge needle (PrecisionGlide™, BD Vacutainer, UK) was inserted into the antecubital 
vein of the participants 
 5ml of blood was drawn into a serum separating tube (SST II Advance, BD Vacutainer, UK) 
 Post blood draw serum separating tubes were inverted 5-6 times in accordance with 
manufacturers guidelines 
 Serum samples were sent to Pathcare laboratories (MediClinic, Stellenbosch, RSA) and serum 
creatine kinase concentration was quantified by means of an activity assay using a 
SYNCHRON LX system (Beckman Coulter, USA) that utilises the chemical reaction outline in 
figure 2.2 to ascertain CK levels. 
 
Figure 2.2 The chemical reaction occurring during the quantification analysis of creatine kinase- [Adapted from 
Chemistry information sheet A18477AK, Creatine Kinase, Synchron systems chemistry information sheet, Beckman 
Coulter 
Increased CK levels will result in increased production of ATP serving as a substrate for two 
coupled enzyme reactions with hexokinase (HK) and glucose-6-phosphate dehydrogenase 
(G6PDH). These enzymatic reactions lead to an increase in reduced β-nicotinamide adenine 
dinucleotide phosphate (NADPH). The NADPH levels are then measured at 340 nm and thus 
giving an indirect measure of CK levels. 
Visit 2: VO2 max testing on a cycle ergometer (VeloTron, Computrainer, USA) was conducted on 
the second visit (see Figure 2.3 for image of VO2max testing setup). Participants were asked not to 
have engaged in any strenuous physical activity for at least 2-3 day before testing.  Prior to 
commencement of test VO2 max testing, the procedure was verbally explained. The VO2 max test 
protocol used was as follows. 
 Participants arrived at the Department of Physiological Sciences’ in-house laboratory at 
their allocated time slot. 
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 5 minutes of dynamic warm-up on a stationary bicycle (VeloTron, Computrainer, USA) was 
performed followed by static stretching of the quadriceps and hamstring muscle groups. 
During the warm up period a verbal explanation was provided to participants with regards 
the need for them to cycle till they reach complete exhaustion in order to obtain an accurate 
assessment of the VO2 max state. 
 Oxygen masks (Vmask, Hans Rudolph, USA) were fitted and tested for air leaks prior to 
commencement of test (Figure 2.4). 
  A metabolic analysis system (Oxycon Pro, Jaeger, Germany) was utilised for breath-by-
breath gas analysis.  
 A continuous ramp protocol was conducted on the cycle ergometer, starting with a 
workload of 100 watt and increasing it by 20 watts every minute. Participants continued to 
pedal as the resistance increased until they were unable to maintain a cadence of >=70. 
The mask in association with the metabolic analysis system recorded the amount of O2 
used by the participant. The values at which the VO2/kg (ml/min/kg) peaked and plateau 
were used to calculate the respective VO2 max. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Cycle ergometer setup for VO2 max testing 
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Visit 3: Participants performed their first attempt at maximal isometric force production. The 
purpose of this visit was to familiarize the participants with the in-house isometric force chair (see 
Figure 2.5) for image of force chair) and testing procedure. The isometric force chair is similar in 
design to a standard leg extension machine that is present in most gyms. Our in house chair was 
designed by the Engineering faculty, University of Stellenbosch. Protocol for isometric force testing 
was as follows 
 
 
 
 
 
 
 
 
30⁰  
Figure 2.4 Subject setup and mask fitting for VO2 max testing – shows the setup procedure for the subjects 
before the start of the starting the test. The mask fitted and all systems were calibrated before connecting the final 
tube connecting the mask with the Oxycon Pro 
Figure 2.5 Isometric force testing apparatus: Shows the chair used in the testing. The screen is connected to 
a computer and is used to visualize the in-test results. The crossbar was setup at 30⁰ from the horizontal axis 
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 Participants performed a five minute warm up that consisted of a slow jog on a treadmill 
(Runrace, Technogym, Italy) followed by a combination of static and dynamic stretching 
focusing particularly on the quadriceps and hamstring muscle groups.  
 Participants were then seated in the chair with the crook of their knee against the seat and 
their back comfortably against the back rest. The crossbar was adjusted to the popliteal 
fossa (crook-of-the-feet) while their feet were under dorsal flexion. The position of the 
backrest and crossbar were noted and entered into the custom computer software 
designed for the chair. 
 The geometric measurements of the knee-ankle, knee-floor, ankle-floor and knee- front-of-
seat measurements shown in Figure 2.6. The hinge angle was set at 30° from horizontal 
axis, to ensure that the quadriceps will be the main contributors to the production of 
isometric force during the test. This angle was consistent throughout the study. 
 
Figure 2.6 Subjects setup concerning geometric measurements 
 Once participant set-up in the chair was completed, they were strapped in to ensure their 
gluteus maximus and lower back were stably positioned against the seat throughout the 
test (Figure 2.7). Participants were initially asked to lightly push against the crossbar and 
then remove their feet from the crossbar completely so that a “zero force reading” could be 
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taken. The protocol was verbally explained to participants followed by the completion of one 
practice attempt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Participants subsequently performed three maximal efforts that involved participants 
pushing their ankles into the crossbar cushion by flexion of the quadriceps muscle group. 
Each of the repetitions was held for 10 seconds, as an isometric contraction, and 20 
seconds rest was allowed between repetitions. Verbal motivation was used during the 
testing to encourage maximal force output. Participants also were provided with a real time 
graphical view of their force output on a computer screen adjacent to the testing chair. 
Visit 4: Participants performed their 2nd attempt at the maximal isometric force production test.  
Visit 5: Baseline muscle biopsies were obtained by a qualified medical doctor from participants. 
Protocol used in obtaining biopsies was as follows 
 Biopsy area on the vastus lateralis was initially cleaned with 70% alcohol.  
 Subsequently a local anaesthetic (2% Lignocaine HCL m/v) and 1: 80 000 nor-adrenaline 
(Xylotox, Adcock Ingram Ltd, Johannesburg, RSA) was injected around the sterilised site 
on the vastus lateralis of the participant.  
Figure 2.7 Subject setup for isometric testing – illustrates the setup, including the strap-in of the participant to 
ensure the gluteus maximus and lower back is kept against the seat. The figure also shows the crossbar at the 
popliteal fossa and the computer stat 
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  A sterile surgical blade was used to make a small incision before a5mm trephine biopsy 
needle (Bergstrom biopsy needle, STILLE, Sweden) with assisted suction extracted the 
skeletal muscle tissue. 
 Post biopsy the skeletal muscle tissue was carefully removed from the biopsy needle and 
placed into cryogenic vials (Corning Incorporated, Mexico) – one for mRNA isolation and 
one for protein isolation. 
 Cryogenic tubes were then placed into liquid nitrogen cooled isopentane (Merck Millipore 
USA) and subsequently stored at -80c until analysis.  
Note - Biopsies were taken from alternate legs. In total 3 biopsies were obtained from each 
participant. For the leg which was biopsied twice the second biopsy was taken 3cm from the site of 
first biopsy. 
Visit 6: Participants arrived at the exercise laboratory at 13:00 for their pre-exercise/2nd baseline 
blood draw and performance of the plyometric exercises. Protocol used for the plyometric jumps 
was as follows. 
 Participants performed a warm up that consisted of 10 minutes of light jogging and static 
stretching for the hamstrings and quadricep muscle groups. 
 Following the warm-up, the proper technique for performing the plyometric jumps was 
explained (see Figure 2.8 for diagrammatic illustration of plyometric jumping technique). 
 Participants were then given a piece of chalk and asked to perform three preliminary 
maximal jumps. At the top of each jump the participant marked the wall with the chalk. 
 The height of the preliminary maximum jumps was measured from the floor and 90% of the 
measured height was calculated and used as the target height for the subsequent exercise 
protocol that consisted of 10 sets of 10 plyometric jump repetitions (100 reps total) with a 
60 second rest between sets. 
 Plyometric jumps were visually monitored to confirm that the participant reached or exceed 
the target height. 
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Visit 7: Participants returned to the exercise physiology lab at Stellenbosch University 4 h (17:00) 
post completion of the plyometric jump protocol in order for biopsies and blood draws to be taken. 
Visit 8: Participants arrived at the exercise physiology laboratory 24 h post performance of their 
plyometric jumps. Biopsies and blood draws were taken at this time point. 
Visit 9: Participants returned to the exercise physiology laboratory 48 h post completion of their 
plyometric jumps in order for a blood draw to be taken at this time point 
Visit 10: Participants completed a maximal isometric force production test 1 week post completion 
of the plyometric jump.  
 
 
 
 
 
 
 
 
Figure 2.8 Technique sequence for plyometric jumps: Shows the proper technique for the execution of the 
plyometric vertical jump [adapted from the MSc Thesis of A. Isaacs, 2012] 
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2.7 Western Blot 
2.7.1 Biopsy homogenization 
 
Skeletal muscle biopsies were homogenized with the Bullet Blender® Storm 5 (Next Advance, Inc. 
USA)  tube containing 100 mg of beads and 1 ml lysis buffer (Tris 50 mM, EDTA 100 mM, 
Benzamidine 1 mM, sodium fluoride 1 mM, PUGNAc 1 mM, Triton X-100 1% (v/v), NP-40 1% (v/v), 
sodium deoxycholate 0.25% (m/v), leupeptin 0.1% (m/v), SBTI 0.4% (m/v), sodium orthovanadate 
100 mM and 1 mM PMSF). 
2.7.2 Protein concentration measurements 
 
Protein concentrations of the samples were measured using a commercial Bicinchoninic acid 
(BCA) kit (BCA protein assay, Thermo Fischer Scientific, USA) and using Bovine serum albumin 
(BSA) (Bovine Serum Albumin Fraction V, Roche, USA) as standards, ranging from 1 mg/ml to      
8 mg/ml. The assay was performed on a 96-well plate (PS microplate, Greiner Bio-One, USA) with 
200 uL BCA added to 10 uL of the sample or standards. All samples and standards were loaded in 
triplicate.  Protein concentration was measured at 595 nm via a plate reader (EL-500 Universal 
Microplate reader, Bio-Tek Instruments Inc, USA).  Concentrations of the samples were calculated 
using the standard curve as reference. 
2.7.3 ABC chondroitinase treatment for decorin probing 
 
Prior to the immunoblotting for decorin, the samples were treated with Chondroitinase ABC from 
Proteus vulgaris (C3667, Sigma-Aldrich, USA) to remove the polysaccharide side chains attached 
to the decorin core protein. Samples (30 µg) were incubated at 37˚C for 6 hours in a buffer solution 
(BSA 0.02%,Tris-HCl 50 mM, sodium acetate 60 mM, pH 8.0) with 36 mU Chondroitinase ABC 
enzyme. Following the 6 hour incubation period, Laemmli sample buffer (237) 0.0625M Tris-HCl (p 
6.8), 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.001% Bromophenol blue) was added and 
the samples were boiled at 95˚C for 5 minutes and the proteins were separated on a 15% 
acrylamide gel. 
2.7.4 Polyacrylamide Electrophoresis and transfer 
 
Polycrylamide gels consisting of a 15% separating gel (0.39 M Tris-HCl (pH 8.8), 15% Acrylamide, 
0.1% SDS, 0.1% APS, TEMED) and a 4% stacking gel (4% Acrylamide, 0.125 M Tris-HCl (pH 6.8), 
0.1% SDS, 0.1% APS, TEMED) were utilised for electrophoresis of protein samples. Gels were 
placed in a Mini Protean Tetra system (Bio-Rad, USA), submersed in running buffer (3.46 mM 
SDS, 25.01 mM Tris base, 191.95 mM Glycine) and electrophoresed at 120 volts until the blue dye 
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present in the Laemmli solution had reached the bottom of the gel. Post electrophoresis gels were 
transferred onto a nitrocellulose (GE Healthcare, Life science, RPN 3032D, UK) membrane via a 
Turbo-blot transfer system (Bio-Rad, USA). Transfers were performed for 30 min at 25 volts and 1 
amp. A Precision Plus Protein™ Kaleidoscope™ marker, (Standards #161-0375, Bio-Rad, USA) 
was used obtain information on protein sizes. Each gel contained at least 2 complete sets of 
samples from 2 participants’ i.e. baseline, 4 h- and 24 h post exercise. Also present in each gel 
was a reference sample, consisting of extra muscle sample that was homogenized, that enabled 
comparison of protein expression between gels.  
2.7.5 Immunodetection protocol 
 
Post transfer blots were stained with Ponceau S for 5 minutes, followed by 3 x washes with dH2O 
(until the background is clear white). The ponceau stained membrane was then captured using on 
a ChemidocMP imaging system (Bio-Rad, USA) that was supported by (Image lab software 4.0, 
Bio-Rad, USA). Images confirmed successful transfer of the proteins on the membrane. Post 
ponceau staining membranes were washed in 1x TBS-T (49.8 mM Tris-HCl (pH 7.6), 149.8 mM 
NaCl, 0.1% Tween-20®) and blocked for 1 h with either semi skimmed milk or BSA (see Table 2.2 
for information on specific blocking used for each antibody). Post blocking membranes were 
washed 1 x 10 minutes followed by 2x 5 minutes with 1X TBS-T. Subsequently membranes were 
then incubated with primary antibodies as outlined in Table 2.2.  Post primary antibody incubation 
membranes were washed 1 x 10 minutes and 2 x 5 minutes with 1X TBS-T followed by a 1h 
incubation at room temperature with the required horseradish peroxidase (HRP)-linked secondary 
antibody. Specific secondary antibodies used for each primary antibody are provided in Table 2.2. 
Post-secondary antibody incubation, membranes were washed 3 x 10 minutes with TBS-T followed 
by addition of enhanced chemiluminescence (ECL). Membranes were subsequently imaged using 
the Chemidoc MP (BioRad, USA) that was supported with Image lab software 4.0 by Biorad. 
Immunoreactive proteins were subsequently quantified using the software and were normalised 
against total ponceau staining. These normalised values were then divided by the value of the 
normalised value of the reference sample which was present on all membranes and thus enabled 
comparison of protein values between membranes.  
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Table 2:2 Antibody optimized conditions for immunoblotting: Shows a summary of all the antibody concentrations, 
blocking substance and concentration, incubation times and secondary concentrations used during immunoblotting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary Antibody 
Blocking with 
primary Ab 
Dilution Blocking Primary Ab Incubation time 
Secondary 
Antibody 
Dilution 
2° Ab 
Incubation 
time 
p-SMAD 2/3 (Goat) Non 1: 1000 3 % BSA Overnight @ 4⁰C Sigma 1: 15000 
1 hour at 
RT 
SMAD 6/7 (Goat) 1% Milk 1: 1000 5 % milk Overnight @ 4⁰C Sigma 1: 10 000 
1 hour at 
RT 
Myostatin/GDF-8 
(Rabbit) 
Non 1: 1000 3 % milk Overnight @ 4⁰C 
Cell 
signalling 
1: 15000 
1 hour at 
RT 
Decorin (Mouse) Non 1:500 3% milk Overnight @ 4⁰C Abcam 1: 10 000 
1 hour at 
RT 
Activin RIIB (Goat) non 1: 1000 5% milk Overnight @ 4⁰C Sigma 1: 15 000 
1 hour at 
RT 
Follistatin (Rabbit) non 1: 1000 3% milk Overnight @ 4⁰C 
Cell 
signalling 
1: 20 000 
1 hour at 
RT 
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2.8 RNA Analysis 
2.8.1 RNA isolation 
 
Approximately 20 mg of skeletal muscle biopsy material was homogenized in 1 ml of TriPure 
(11667157001, TriPure Isolation Reagent, Roche, Switzerland)  using specialized beads in 
association with the Bullet Blender® Storm 5 (Next Advance, Inc. USA), and according to the 
manufacturer’s instructions for skeletal muscle. Total RNA was isolated from the Tripure solution 
according to the manufacturer’s guidelines, which briefly entailed the following steps: 
Step 1- Chloroform was mixed with the TriPure solution that contained the homogenised skeletal 
muscle lysate in a 1:5 ratio (cholorform:Tripure) and left at room temperature for 10 minutes.  
Step 2 - Samples were then centrifuged at 12 000x g for 15 minutes, resulting in a 3 tier physical 
separation of the RNA (top layer), DNA (middle layer) and proteins (bottom layer in the lysate). The 
top layer containing the RNA was carefully removed and transferred to a new RNAse free tube 
(Ambion, USA). 
Step 3 - Isopropanol was then added in an equal volume to the removed RNA. Samples were 
inverted several times to mix the two solutions and then left at room temperature for 10 minutes. 
Step 4- Samples were centrifuged at 12 000x g for 10 minutes, resulting in the formation of an 
RNA containing pellet at the bottom/side of the tube. Supernatant was removed from the tube and 
400 µL 70% ethanol was added to the tube to wash the pellet.  
Step 5- Samples were centrifuged again at 8 500x g for 6 minutes. Following the centrifugation, the 
supernatant was aspirated and the tubes were left open at room temperature for 5-10 minutes to 
remove any residual ethanol. 
Step 6 -The isolated RNA was re-suspended in TE buffer (10 mM Tris (pH8), 1 mM EDTA)(AM 
9847, Ambion, USA) and stored at -20o C until use. 
To check for quality of the RNA 500 ng of RNA was run on an agarose gel and thereafter 
visualized on the ChemidocMP (BioRad, USA) to evaluate if the 18s and 28s ribosome were intact 
as a quality control step. 
2.8.2 Reverse Transcription 
 
Concentration of the isolated RNA was determined by a NanoDrop Mini (Thermo Fischer Scientific, 
USA) and 1 µg of the isolated RNA was treated with DNAse according to the manufacturer’s 
guidelines (#04716728001, DNase I recombinant, RNase-free, Roche, Switzerland) to remove any 
residual DNA carryover from the isolation process.  
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Subsequently a commercial reverse transcription kit (Transcriptor first strand cDNA synthesis, 
#04896866001, Roche, Switzerland) was used to reverse transcribe the DNAse treated RNA into 
cDNA with random hexamers in accordance with the manufacturers‘guidelines.  
2.8.3 Primer Design 
 
The NCBI database (www.ncbi.nlm.nih.gov) was used to obtain sequence information pertaining to 
the human decorin mRNA transcripts A1 (NM_001920.3) and A2 (NM_133503.2) and GAPDH. 
Sequence present in Exons 1 and 2 of decorin A1 were used to design decorin A1 specific primers 
as these two exons are only in dercorin A1. Primers specific for decorin A2 were designed using 
sequence present in exons 1 and 2 of decorin A2 as these two exons of only present in decorin A2.  
All of the a fore mentioned sequences fordecorin A1, A2 and GAPDH were inputted into the free 
online primer design tool OligoPerfect™ available at http://tools.lifetechnologies.com. Primer 
sequences for DecorinA1, A2 and GAPDH are provided in Table 2.3 
Table 2:3 Semi-Quantitative mRNA analysis primer information: Shows the details pertaining to the primers that was 
designed and custom made for the analysis of A1 and A2 decorin mRNA variants in human skeletal muscle. 
Furthermore, the table also include information of the GAPDH primer used to confirm cDNA loading in all samples. 
 
 
 
 
 
 
Primer sets 
(Sigma-Aldrich, USA) 
Sequence Amplicon size Bp Tm (C⁰) GC % 
Dec A1 Forward 
 
ATTGTGTTCATTGAGGGAAACC 
260 
22 63.7 40.9 
Dec A1 Reverse 
 
AGCAGAAGGAGGATGATAGTGG 
22 63.4 50 
      
Dec A2 Forward 
 
ATCGTCTAGTGAGGGACAGACC 
260 
22 63.4 54.5 
Dec A2 Reverse 
 
GCAAGCAGAAGGAGGATGATAG 
22 64.0 50 
      
GAPDH Forward AATCCCATCACCATCTTCCA 
716 
20 56.17 45 
GAPDH Reverse TGACAAAGTGGTCGTTGAGG 20 58.05 50 
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2.8.4 Semi quantitative PCR 
 
Total volume of each PCR was 25 µL that consisted of the following 2 µL of cDNA (50 ng),  1.25 uL 
forward and reverse primers (primer concentration per reaction being 1 uM), 8 uL nuclease free 
H20 and 12.5 uL of the PCR mastermix  (#04710444011, FastStartPCR Master, Roche, 
Switzerland). All PCR experiments were carried out on a thermocycler (2720, AppliedBiosystem, 
USA) in accordance with PCR mastermix manufacturers’ guidelines. Briefly the steps for each 
PCR was as follows 
Step 1: 5 minutes at 95⁰C 
Step 2: 15 seconds at 95⁰C 
Step 3: 30 seconds at 56⁰C    40 cycles 
Step 4: 1 minute at 72⁰C 
Post PCR samples were mixed with 6 µL loading buffer (75% v/v glycerol, 0.02% w/V bromophenol 
blue, 10 mM Tris Base, 1 mM EDTA, 0.2% w/v SDS) and loaded onto a 1.5% agarose gel 
containing sybr safe DNA gel stain (#533102, Invitrogen, Life Technologies, USA) at 1X 
concentration. The samples were electrophoresed using a Gel XL Ultra electrophoresis system 
(Labnet International, USA) and 1x TBE running buffer (89 mM Tris Base, 89 mM Boric Acid, and 3 
mM EDTA). Gels were electrophoresed at 50 V for about an hour or until the bromophenol blue 
dye had reached the halfway point of the gel. A 100 bp ladder (15628-050, 100 bp DNA ladder, 
Invitrogen™, Life Technologies, USA) was run alongside the samples for visualization of the 
product size. The gels were visualized on a Chemidoc MP (Bio-Rad, USA) and analysed by using 
Image Lab software 4.0 (Bio-Rad, USA). To confirm identity of detected amplicons, bands of the 
correct base pair length were excised from the gel under an UV-light. Subsequently gel pieces 
were sent to the Central Analytical Facility (University of Stellenbosch, Stellenbosch, RSA) for 
sequencing. Results obtained from sequence reaction were then aligned to the NCBI human 
genome and transcript database via use of the basic local alignment search tool software available 
at http://blast.ncbi.nlm.nih.gov/Blast.cgi.  
2.8.5 Quantitative PCR (qPCR) 
 
TaqMan® probe chemistry was used for (qPCR). TaqMan® probes used for detection of decorin 
were Hs01072200_m1 which could detect decorin transcripts A1 (NM_001920.3) and A2 
(NM_133503.2) while TaqMan®Hs01075781_m1 probe could detect decorin transcript A2 (see 
Table 2.4). 
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Each reaction for qPCR consisted of the following – 10 uL TaqMan® gene expression master mix, 
1uL TaqMan® probe, 1.2uL cDNA (30 ng) and 7.8 uL of nuclease free H20 to give a total volume of 
20 uL. All samples were run in duplicate in 96 well qPCR plates (#4483352, MicroAmp® 
EnduraPlate™ Optical 96-Well Clear Reaction Plates, Life Technologies, USA) on a 
StepOnePlus™ Real-Time PCR system (4376600, Life Technologies, USA) with the 
accompanying StepOne™ Software v2.2. The settings for the thermocycler was as follows: 2 
minutes at 50⁰C followed by 10 minutes at 95⁰C, then 40 cycles of 15 seconds at 95⁰C followed by 
1 minute at 60⁰C.  
 
Table 2:4 Information on the probes used in the quantification of the genes with real-time PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cat probe Target transcripts 
Exon 
boundaries 
Amplicon length 
Hs01072200_m1 NM_001920.3Decorin A1 
4-5 102 
 NM_133503.2Decorin A2 
Hs01075781_m1 NM_133503.2Decorin A2 1-2 108 
Figure 2.9 RT-PCR amplification regions for specific probes– Shows the exon map for the decorin [Homo 
sapiens] gene with different initiation sites (1a and 1b) for the two mRNA variants of interest. The figure also 
shows the exon boundaries for the specific probe 
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2.8.6 Quantification of data 
 
Expression levels were quantified using the comparative 2-∆∆CT calculation method (238) using 
beta-2-microglobulin as the house keeping gene. TaqMan® probe used for B2M was Hs00984230. 
A reference sample, which was one of the samples from another participant, was also included on 
each plate and all samples were normalised to this. 
2.9 Statistical Analysis 
 
All statistical analysis was performed with STATISTICA software 11.0 (StatSoftInc, USA). Normal 
probability plots were constructed for all data to assess the normality assumptions of the data. 
Mixed models repeated measures ANOVA and Fisher LSD post-test was perform on all data to 
conclude significant differences between mean values of different time points. Standard deviations 
are shown on bar graphs and statistical significance are indicated when p ≤ 0.05. 
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3 Chapter 3: Results 
 
3.1 Baseline data 
 
Anthropometric measurements, age profile and VO2 max values of participants whom completed 
this study are provided in Table 3.1.  
Table 3:1 Summary of the subject’s baseline characterization values: Data are shown as mean values ± standard 
deviation (SD). Values reported are from the selected group of participants continuing with the study after the screening 
sessions.  
 
 
 
 
 
 
 
 
 
 
 
 
 Study (n=15) 
Age (years) 21 ± 2.56 
Height (cm) 179.17 ± 3.44 
Weight (kg) 77 ± 15.69 
Body mass index (BMI) (kg/m2) 23.93 ± 4.46 
VO2 max (ml/kg/min) 44.1 ± 4.38 
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3.2 Effect of an acute bout of plyometric jumping on maximal isometric force 
output 
 
In order to ascertain the effects of an acute bout of plyometric jumping on skeletal muscle, 
participants maximal isometric force production of the quadriceps muscle group was measured via 
a custom built isometric force chair. Participants were assessed pre performance of plyometric 
jumps, immediately after completion of the plyometric jumping protocol and 1 week after 
completion of plyometric jumps. A significant (p = 0.045) decrease in force production was 
observed immediately after (12.02 N/kg ± 1.73 SD) completion of plyometric jumps compared to 
baseline values (13.08 N/kg ± 2.49 SD) and 1 week (13.38 N/kg ± 2.24 SD). The significant 
reduction (10%) in force output immediately after completion of the plyometric jumping protocol 
indicates that the protocol did indeed affect voluntary force production. While the return to baseline 
isometric force output values 1 week post completion of the protocol demonstrates that 1 week is 
sufficient for skeletal muscle of participants to recover their force production capabilities after a 
plyometric jumping intervention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Maximal isometric force production changes over time – Error bars in the graph represent standard 
deviation (SD). (* = p < 0.05)(n=15) 
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3.3 Effect of an acute bout of plyometric jumping on serum creatine kinase levels 
 
Participant’s serum creatine kinase levels were measured at baseline and at 4, 24 and 48 h post 
completion of the plyometric jumping protocol. A significant increase (p< 0.05) in serum creatine 
kinase levels was observed at all-time points assessed post completion of the plyometric jumping 
protocol compared to baseline levels. The highest creatine kinase levels were observed at 24 
hours (626.92 u/L  ±496.81 SD) with slightly lower levels being present at 4- (422.69 u/L ± 429.17 
SD) and 48 h (452.08 u/L ± 172.46 SD) post completion of the plyometric jumping protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Serum creatine kinase response over time – Error bars represent standard deviation (SD)(n=15). * p<0.05, 
** p<0.01, *** p<0.001 
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3.4 Molecular adaptation of skeletal muscle in response to an acute bout of 
plyometric jumping 
 
3.4.1 Myostatin protein expression 
 
Myostatin protein expression values were assessed via SDS PAGE and immunodetection. A 
commercial antibody directed towards a region spanning from the 300th amino acid to the C-
terminal of myostatin was utilised (Anti-Myostatin antibody, ab98337, Abcam). The predicted 
molecular weight of myost  atin is 42.76 kDa, however, this immature myostatin undergoes two 
cleavage events; one to remove the signal peptide and a second cleavage event to split the protein 
into two N- and C-terminal fragments. The predicted weights of these fragments are approximately 
30 and 13 kDa respectively. The commercial antibody used here was capable of detecting an 
immunoreactive protein migrating at approximately 43 kDa which is close to the size of the full 
length precursor monomer (ie including the signal, N-terminus and C-terminus). Quantification of 
this 43 kDa protein did not show any significant difference in protein expression between the three 
time points analysed (baseline, 4 h post- and 24 h post plyometric jump protocol). 
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Figure 3.3 Myostatin protein analysis – A) Myostatin precursor protein visualized and indicated at 43 kDa.B) Successful 
transfer of proteins onto the membrane and visualized by ponceau stain, serving as normalization for protein loading. C) No 
significant changes were observed in relative protein concentration over time in response to eccentric exercise. (n=10) S= 
Subject (Reference sample was an human skeletal muscle sample used at the same concentration across all blots) 
43 kDa 
A. 
B. 
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3.4.2 Activin IIb receptor 
 
As discussed previously (175,181) myostatin exerts it cellular effects via binding to the activin 
receptor complex. Therefore it was of interest to determine whether protein expression levels of the 
activin receptor were altered in response to plyometric exercise training. A commercial antibody 
which was raised against a recombinant human fragment immunogen was used (Anti-Activin 
Receptor Type IIB antibody, ab10596, Abcam). The predicted molecular weight of the activin 
receptor is 57.7 kDa. An immunoreactive protein was detected which migrated at 55-60 kDa (top 
band on Figure 3.4.A). A faint second band was detected at approximately 50 kDa. The identity of 
this second band is currently unknown. Quantification of the approximate 55-60 kDa 
immunoreactive protein found no significant differences in protein expression between time points. 
 
 
 
 
 
 
 
 
 
55 kDa 
A. 
B. 
Figure 3.4 ActivinIIb receptor protein analysis - A) ActivinRIIb protein observed at 55 kDa.B) Successful transfer of 
proteins onto the membrane and visualized by ponceau stain, serving as normalization for protein loading.C) No 
significant differences in protein concentration across time (n=7) S= subject (Reference sample was an human skeletal 
muscle sample used at the same concentration across all blots) 
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3.4.3 Phosphorylated Smad 2 and 3 
 
Post myostatin binding to the activin IIB receptor an intracellular signalling cascade is initiated 
whereby the Smad proteins play a key role in transmitting the anti-muscle growth properties of 
myostatin (discussed in detail in Zhu et al (2004)(185)). Measurement of phosphorylated Smad 
(pSmad) 2 and 3 levels was conducted via the use of a commercial antibody (Anti-p-Smad 2/3 (Ser 
423/425) antibody, sc-11769, Santa Cruz) which was raised against a short proprietary amino 
acids sequence containing Ser 423 and Ser 425 and which could detect both phosphorylated 
Smad2 and 3 by means of a homologous region in both Smad2 and 3. The predicted size of 
Smad2 and 3 was 52.3 kDa and 48 kDa, respectively. A quite faint immunoreactive protein was 
detected at approximately 50 kDa, which is in close size agreement with pSmad2 and 3. No 
second immunoreactive protein was clearly detected therefore the immunoreactive protein that 
was detected at approximately 50 kDa was assumed to represent both pSmad2 and 3. 
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Figure 3.5 Phosphorylated Smad 2,3 protein analysis –A) pSmad2,3 proteins visualized and indicated at 50 Da. B) 
Successful transfer of proteins onto the membrane and visualized by ponceau stain, serving as normalization for protein 
loading. C) No significant changes were observed in relative protein concentration over time in response to eccentric 
exercise (n=9) (Reference sample was an human skeletal muscle sample used at the same concentration across all 
blots) 
Stellenbosch University  http://scholar.sun.ac.za
50 
 
Copyright © 2014 Stellenbosch University   All rights reserved  
 
3.4.4 Smad 7 
 
While the Smad proteins 2 and 3 are positive regulators of myostatin signalling Smad7 is a 
negative regulator. Therefore it was of interest to investigate Smad7 protein levels to ascertain 
whether there were increased or decreased Smad7 levels in response to the plyometric jumping 
protocol. A commercial antibody directed towards the N-terminal region of Smad7 was utilised 
(Anti-Smad6/7 antibody (N-19), sc-7004, Santa Cruz). Within the NCBI database 3 isoforms of 
human Smad7 as listed with molecular weights of 46.4, 23.9 and 46.3 kDa. The commercial 
antibody used here detected immunoreactive proteins migrating at approximately 50-55 kDa 
(Figure 3.6 A). The lower immunoreactive protein that migrated at approximately 50 kDa and 
hence closer in size to the predicted 46.4 kDa Smad7 protein was quantified. No significant 
difference was observed in expression levels between the time points (see Figure 3.6 C). 
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Figure 3.6 Smad 7 protein analysis – A) Smad 7 protein visualized and indicated at approximately 50 kDa. B) Successful 
transfer of proteins onto the membrane and visualized by ponceau stain, serving as normalization for protein loading. C) No 
significant changes were observed in relative protein concentration over time in response to eccentric exercise (n=10) 
(Reference sample was an human skeletal muscle sample used at the same concentration across all blots)\ 
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3.4.5 Follistatin 
 
Follistatin is a negative regulator of myostatin signalling as it can bind to and subsequently inhibit 
receptor and downstream signalling activation (189). To assess for follistatin protein expression a 
commercial antibody (Anti-follistatin antibody, ab47941, Abcam) was utilised which was raised 
against a recombinant full length follistatin. The predicted molecular weight of follistatin is 38 kDa 
and an immunoreactive protein migration at approximately 38 kDa (Figure 3.7 A) was observed 
and is in agreement with the size reported in other literature (239). Follistatin protein expression 
was significantly increased at 4 h (2.1 fold increase of the means, p = 0.007) and 24 h (2.43 fold 
increase of the mean p = 0.004) post plyo compared to baseline levels (p < 0.01)(Figure 3.7 C). 
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Figure 3.7 Follistatin protein analysis – A) Representative follistatin Western blot image with detection of 
immunoreactive protein migrating at 38kDa B) Successful transfer of proteins onto the membrane and visualized by 
ponceau stain, serving as normalization for protein loading C) Significant changes were observed in relative protein 
concentration between baseline and 4 h post exercise and also between baseline and 24 h post exercise (p< 
0.01)(n=12) (Reference sample was an human skeletal muscle sample used at the same concentration across all blots) 
Stellenbosch University  http://scholar.sun.ac.za
52 
 
Copyright © 2014 Stellenbosch University   All rights reserved  
 
3.4.6 Decorin 
 
Decorin mRNA 
Decorin has been reported to be capable of binding myostatin (191) and hence it may also exert 
regulatory control of myostatin. Currently there is limited or no expression information relating to 
decorin in adult human skeletal muscle. Therefore the NCBI gene database 
(http://www.ncbi.nlm.nih.gov) was investigated to obtain information relating to the human decorin 
gene. Multiple splice variants of decorin were found to be present in the human genome as shown 
in Figure 3.8 
 
Due to financial and time restraints a focus of investigation was placed on two decorin mRNA 
transcripts NM_001920.3 hereafter referred to as A1 and NM_133503.2 hereafter referred to as 
A2, which both encode the same decorin protein, however their transcription start sites differ. Such 
a difference is suggestive that they may be under different regulatory control by transcription 
factors. Primer sets were designed that were specific to each transcript and subsequently PCR 
was performed on cDNA obtained from 3-5 of the participants at baseline, 4hr and 24hr post 
plyometric exercise. Primer sets 1 and 2 that were specific to A1 and A2 respectively were both 
predicted to detect amplicons at a size of 260 nucleotides respectively. In all samples analysed 
amplicons of the expected size were obtained for A1 and A2 (see Figure 3.9). To confirm 
unambiguously, the identity of the amplicons they were excised from the agarose gel and 
sequenced. The sequence data obtained confirmed the amplicons to be the decorin transcripts A1 
and A2.To obtain further information relating to decorin mRNA expression quantitative PCR 
(qPCR) was performed using TaqMan® probes. One probe was designed to pick up both decorin 
transcripts while a second probe was designed to pick up just the A2 decorin transcript. At the time 
of conducting these experiments no commercially available TaqMan® probe was available to 
specifically detect decorin transcript A1. 
Figure 3.8 Decorin mRNA variants and exon map [Adapted from http://www.ncbi.nlm.nih.gov/gene/1634] 
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 No significant difference was found to be present in mRNA expression levels of decorin when 
either both decorin transcripts A1 and A2 were measured or when only decoding transcript A2 was 
measured (see Figure 3.10 A and B).  
Decorin Protein 
To investigate decorin protein expression a commercial antibody that was directed towards aa 1-
359 of decorin was initially utilised (Anti-decorin antibody, ab54728, Abcam). However no signal 
was detected (data not shown). The decorin protein is highly post-translationally modified (209) 
and hence these modifications may affect antibody binding. Therefore an alternative strategy was 
employed whereby decorin was treated with ABC chondroitinase an enzyme that catalyzes the 
eliminative degradation of polysaccharides containing (1-4)-β-D-hexosaminyl and (1-3)-β-D-
glucuronosyl or (1-3)-α-L-iduronosyl linkages to disaccharides containing 4-deoxy-β-D-gluc-4-
enuronosyl. ABC chondroitinase is regularly used in studies pertaining to decorin (240–242) and a 
study by Li et al. (2013)(243) illustrated the differences in immunoblotting results obtained from 
samples treated with the enzyme compared to untreated. Results from SDS PAGE and immune 
detection found two immunoreactive proteins migration at 42 kDa and 38 kDa which are likely 
decorin proteins as similar sized proteins have been reported by Li et al. (2013)(243).However 
additional antibodies will be required to be used to unambiguously confirm these immunoreactive 
proteins to be decorin and also to give clearer bands which can be accurately quantified. Such 
experiments are planned for the future however they were outside the time scale available to this 
project and hence no quantification of decorin protein expression levels was performed.  
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3.4.6.1 Decorin - Semi-quantitative PCR 
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Figure 3.9 Semi-quantitative mRNA analysis of decorin splice variants –  A) Agarose gel image obtained with 
Decorin primer set 1 specific for decorin transcript A1.B) Agarose gel image obtained with Decorin primer set that was 
specific for decorin transcript A2  C) GAPDH primer set that served as positive control for quality of cDNA. S= subject 
(Negative control possessed all the ingredients for the reaction, except DNA substrate). 
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3.4.6.2 Decorin – Real time PCR (RT-PCR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
Figure 3.10 Quantitative analysis of decorin variants – A) Decorin gene expression over time for probe 2200: Analysis 
on the expression of Decorin with the designated probe, revealed no significant differences (n=4). However, the graph 
illustrated a slight pattern in which expression is lower at 4 hours post exercise compared to the other time points. B) 
Decorin gene expression overt time for probe 5781: Expression of decorin A1 and A2, over the selected times reveal no 
significant differences (n=5), but it can observe that higher levels of decorin expression are present at 24 hours post 
exercise. 
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3.4.6.3 Decorin – protein 
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B. 
A. 
Figure 3.11 Decorin Western blot analysis after enzyme treatment - A) The blot shows bands corresponding to 
the size of the chondroitinase ABC enzyme (90 kDa) used to cleave the glycosylated side chains, whereas the decorin 
protein band is shown close to the 42 kDa. Additional band at 38 kDa may be isoforms not yet analysed. The ponceau 
S image (Figure B) showed successful transfer of proteins onto the nitrocellulose membrane, but also revealed 
changes in the appearance of the other proteins on the blot when compared to the images obtained from other 
Western blot analysis, which do not use the enzyme (data not shown). Note – subject 2 (S2) only has two time points 
biopsies, because of a logistical error during the study 
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4 Chapter 4: Discussion 
 
4.1 Model: an acute bout of unaccustomed eccentric exercise induces muscle 
damage 
4.1.1 Creatine kinase 
 
The eccentric exercise employed in this thesis was plyometric jumping. When performing 
plyometric jumps the knee extensors muscle groups are forced to undergo eccentric contractions 
and it is from this muscle group whereby biopsies were obtained. Previously this mode of exercise 
has been reported to induce muscle damage via disruption to the sarcomere structures (28). The 
indirect skeletal muscle damage indicator creatine kinase was used here in order to confirm the 
occurrence of muscle damage while maximal isometric muscle contractions were measured to 
assess for the impact of muscle injury on force output. Post-performance of plyometric jumps 
creatine kinase levels were significantly elevated at both the 4, 24 and 48 h time points compared 
to baseline levels. These increases in creatine kinase levels are strongly supportive of the 
occurrence of skeletal muscle damage as CK is typically bound to the I-band within the 
sarcomeres and to the M-line of the sarcoplasmic reticulum (47) and hence is intracellular and not 
in the serum. Performance of eccentric muscle contractions is known to generate increased 
tension within sarcomeres (26). The increased tension leads to disrupted sarcomeres (23,29) and 
also ruptured membranes thus likely impacting on the anchors that typically keep CK intracellular. 
Loss of CK anchorage and membrane rupture would result in CK release into circulatory system. 
CK levels peaked 24 h after the plyometric jumping and had decreased from these peak levels at 
48 h post exercise.  
A similar pattern of CK serum levels has previously been reported in a study performed by our 
research group using the same eccentric (plyometric jumping) exercise protocol (28). The referred 
study reported values of 529 ± 318 SD U/L at 1 day post exercise versus 627 U/L ± 497 SD in the 
current study. We emphasize this study by Macaluso et al. (28) as not many studies exist which 
use the plyometric jumping as the form of eccentric exercise and for the fact that damage was 
confirmed by several methods including serum creatine kinase, immunofluorescence analysis of 
membrane disruption and transmission electron microscopy (TEM) analysis of Z-disk streaming. 
The analyses revealed loss of dystrophin staining showing that type II fibers were more susceptible 
to damage from plyometric jumps, while TEM showed structural disorganization in post exercise 
samples (28). Due to unforeseen circumstances, no immunohistochemistry (H & E staining) or 
immunofluorescence (dystrophin staining) could be performed in the present study, which may 
have revealed more about the extent of damage sustained during the exercise intervention. 
Stellenbosch University  http://scholar.sun.ac.za
58 
 
Copyright © 2014 Stellenbosch University   All rights reserved  
 
However, the use of serum creatine kinase analysis in this study was mainly to report significant 
data indicating that skeletal muscle damage did indeed occur.  
The significant increase in CK at the 24 h time point coincides with the time point at which the peak 
presence of neutrophils is observed in injured muscle (59). The high concentration of enzymes 
released by activated neutrophils in skeletal muscle at this time point likely represents secondary 
damage occurring as a result of mechanisms for the removal of disrupted myofilaments and other 
cytosolic structures (244), hence resulting in increased CK release. The reduction in CK levels at 
48 h compared to 24 h likely represents a combination of creatine kinase clearance by the kidneys, 
creatine kinase degradation in the circulatory system and also of reduced creatine kinase release 
from skeletal muscle. 
4.1.2 Reduced isometric force production 
 
Performance of eccentric exercise has previously been reported to result in decreased force 
production capabilities of the exercised muscle (67). Results obtained during the course of this 
thesis are in agreement with such findings. The knee extensors muscle group of participants which 
is a muscle group that is subjected to eccentric contractions during plyometric jumping showed a 
significant decrease in maximal isometric force production immediately post performance of the 
plyometric jumping exercise. This reduced force output is likely largely explained due to the 
structural damage that has previously been reported to occur in the sarcomeres of eccentrically 
contracted muscle during unaccustomed eccentric exercise (32). Interestingly the attenuated force 
production capabilities reported here in this thesis (10% reduction after exercise) do not concur 
with other studies that report larger decreases in force production post eccentric exercise (32-50%, 
depending on the angle)(64,67–69). Furthermore we observed that 1 week post performance of 
the plyometric jumping exercise that there was no significant difference in force output levels 
compared to baseline levels which is in contrast to previous studies which have reported 
decreased muscle force outputs lasting for several weeks following performance of unaccustomed 
eccentric exercise (70). 
The reason for these contrasting results may be due to different modes of eccentric exercise used 
and hence, depending on the mode of exercise (e.g. plyometric jumping, eccentric barbell squats 
(67) or isokinetic dynometer (64), more or less damage may be accrued by participants. An 
analysis of sarcomere disruption in response to different eccentric modes of exercise would be 
useful in ascertaining which modes of eccentric exercise induce the least or greatest sarcomere 
disruption. The use of a uniquely built apparatus for our laboratory may also attribute to differences 
in results when comparing to other apparatus. Due to relatively large differences observed in force 
reductions between this study and those mentioned previously, it is likely a combination of factors 
that are responsible for the differences. Further studies using this apparatus, may need to use the 
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same exercise protocol as used in this study, to conclude if the variance, when comparing to other 
studies results, are caused by the apparatus or from inexperience occurring in this study. 
In combination the elevated CK levels and reduction in maximal isometric force production provide 
support that the plyometric jumping protocol used here exerted a stress upon skeletal muscle that 
should have stimulated hypertrophy signalling cascade. Therefore a suitable environment was 
created for the investigation of myostatin and some of its associated regulatory factors in order to 
gain insight into the temporal signalling process that occurs to enable hypertrophy of skeletal 
muscle in response to eccentric contractions (227). 
4.2 Human skeletal muscle myostatin response to eccentric exercise 
 
Removal of myostatin from the mouse and human genome results in the production of significantly 
more muscular mice and humans respectively (142,147). While elimination of genes is certainly a 
useful technique in identifying their physiological function it does not provide any information on 
how the “knocked out” gene achieves that function. Therefore considering that the vast majority of 
the human population have a functioning myostatin gene present in their genome it is important to 
learn more about how it functions in promoting skeletal muscle growth so that these pathways can 
then potentially be targeted to improve muscle hypertrophy when required. Investigation of 
myostatin protein expression in the acute stages post performance of the plyometric jumping 
protocol did not show any significant difference in expression levels of an approximate 43 kDa 
protein that closely matches the predicted size of full length myostatin. This seems to be in line 
with some exercise studies (206,207,230), while it may be somewhat unexpected when 
considering that most studies reported a decrease in myostatin mRNA after exercise (see Table 
1.1)(228,232,233,235).  
It is interesting to note that the full length or precursor myostatin undergoes two separate cleavage 
events in order for it to be able to bind to the activin type IIb receptor and hence become 
biologically active (176).  Fragments of different sizes 26-30 kDa (mature dimer) and 13 kDa 
should therefore be detectable. However, none of these fragments were clearly detectable with the 
commercial antibody used here which was directed towards the C-terminal region of myostatin. 
Such a finding is suggestive that very limited myostatin cleavage typically occurs in human muscle 
at baseline levels and during the acute phase following plyometric jumping thus making detection 
of the biologically active C-terminal portion of myostatin difficult. Also, additional antibodies may 
need to be used which have a higher affinity levels than the one used here which may have more 
success in detecting the C-terminal active dimer. It may be wise to use many different myostatin 
antibodies, to clearly detect all different myostatin forms which, along with genetic and protein 
analysis of the enzymes responsible in the post expression processing, may clarify this whole 
process and how it is affected by exercise compared to maybe an atrophy setting like cachexia.  
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The clear detection of the 43 kDa myostatin protein without the clear detection of the mature active 
myostatin protein, demonstrates that the majority of myostatin present in adult human skeletal 
muscle is in its inactive forms at baseline and at the time points after exercise. At these time points 
the volunteers were in the rested state, thus highlighting the importance of also assessing the 
myostatin regulatory factors which may have longer half-lives than active myostatin. It will therefore 
be of future interest to examine some of the proteins that have been reported to be capable of 
cleaving the myostatin precursor protein and producing the biologically active form. Overall the 
findings presented here shed new light on myostatin protein expression in adult human muscle as 
most studies to date have investigated myostatin changes by assessing expression only at the 
mRNA level in humans (229,230,232,235,245).  
4.3 Downstream signalling of myostatin in response to eccentric exercise 
 
4.3.1 Activin type IIB receptor 
For myostatin to exert its effect on muscle cells it must bind to its receptor activin type IIb receptor 
(175). No data is currently available regarding the activin type IIb receptor in human skeletal 
muscle post performance of eccentric exercise such as plyometric jumping (according to Pubmed 
searches). Analysis of its expression with a commercial antibody revealed the presence of two 
closely sized immunoreactive proteins that migrated at approximately 55 kDa and 60 kDa. The 
reason for the detection of two bands is possibly that it is a result of post translational 
modifications. The use of second antibody may clarify the legitimacy of this suggestion. 
Alternatively, non-specific binding of the primary antibody or simply prosthetic groups may explain 
the second band. The bigger of these two proteins more closely matched the predicted size of 
receptor (58 kDa) and displayed a more consistent and detectable expression pattern. Quantitative 
analysis did not yield any specific differences in expression however significant variation was 
observed among subjects. With variations in expression of approximately 5-6 fold. This variation 
requires further investigation in a larger group of people to establish whether receptor expression 
levels may be linked to smaller muscle mass as it could be hypothesised that more receptors may 
result in more efficacious myostatin signalling. In partial agreement with such a hypothesis it has 
been reported that treatment of human skeletal muscle cells in vitro with an antibody that targets 
activin type II receptors (and hence prevents myostatin binding) induces hypertrophy (175). 
Additional information on the expression pattern and cellular localisation of the activin type IIb 
receptor in human skeletal muscle post eccentric exercise and at later time points during the 
recovery period will provide useful information on how this receptor may function in regulating 
muscle hypertrophy in vivo. 
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4.3.2 Phosphorylated Smad 2 and 3 
Downstream of activin type IIb receptor in the myostatin signalling pathway lies the Smad family 
members 2 and 3 that are phosphorylated in response to myostatin binding (184,185). In 
agreement with our data showing no change in myostatin protein levels no significant change was 
observed in pSmad2 and 3 levels. This suggests that during the acute stages (24hr) of recovery 
following the plyometric jumping protocol, there is no involvement of the myostatin signalling 
pathway and that it is likely at later time points whereby myostatin may exert its effect on skeletal 
muscle hypertrophy. Further support for such a hypothesis are the results that were obtained for 
Smad7 which is known as the inhibitory Smad due to its ability to inhibit the Smad signalling 
pathway via the interruption of Smad phosphorylation at the Activin receptor intracellular kinase 
domain (187). Smad7 expression levels have been reported to be controlled by the Smad3/4 
complex as this complex binds within the promoter region within Smad7 (246). The Smad3/4 
complex is formed only when Smad3 is phosphorylated (185) such as that which occurs in 
response to myostatin binding to the activin type IIb receptor (184).  
This regulation of Smad7 by the Smad3/4 complex therefore creates an autoregulatory loop for 
myostatin signalling and an additional read out of its activity which as mentioned previously, 
appears to be very low during the acute stages following plyometric exercise. It will be of future 
interest to study later time points post performance of eccentric exercise to gain a better 
understanding of the temporal expression of the Smad proteins 2/3 and 7.   
4.4 Myostatin regulatory proteins 
 
4.4.1 Follistatin 
One of the proteins in the human proteome that is capable of regulating myostatin function is 
follistatin, which is an autocrine glycoprotein. Follistatin can bind to myostatin and hence inhibit 
myostatin's ability to interact with the activin IIb receptor (175). Thus follistatin was a protein of 
interest for this thesis. Present within the human proteome are two known isoforms of follistatin 
termed Fst317 (317 aa, NP_006341.1) and Fst344 (344 aa, NP_037541.1). No study to date has 
specifically investigated if both isoforms are present in human skeletal muscle. Results from 
Western blots performed on protein lysates of participants highlighted the presence of an 
approximate 38 kDa sized protein that closely matches the predicted size of Fst344 and also 
matches the predicted size as per antibody datasheet. No clearly detectable immunoreactive 
protein at approximately 34.8 kDa, the predicted size of Fst317, was present. The commercial 
antibody used here was raised against a full length recombinant follistatin. Therefore the specific 
antigen recognition site/s of the antibody is unknown thus this antibody may not be able to detect 
Fst317. Alternatively Fst317 may not be expressed in adult human skeletal muscle. An analysis of 
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follistatin mRNA in human skeletal muscle should be performed to rule out the presence of Fst317. 
It is noteworthy that when the Fst344 isoform is virally expressed in macaque monkeys that 
significant muscle hypertrophy occurs (247). In light of such a finding it is interesting that the 
approximate 38 kDa protein detected here, that matches the predicted size of Fst344, was 
significantly upregulated at both 4 and 24 h post completion of the plyometric jumping exercise. 
This increase in follistatin is likely to create a favourable environment for muscle regeneration and 
growth. How follistatin achieves the promotion of skeletal muscle hypertrophy is still unclear. One 
potential mechanism is through aforementioned negative regulation of myostatin. However when 
follistatin is overexpressed in mice from a myostatin null background significantly more muscular 
mice develop compared to mice that are only myostatin-/- (203). Such a finding provides support 
that follistatin interacts with other possible negative muscle regulators or promotes the activity of 
positive muscle growth regulators. With developments in whole proteome analysis such as the use 
of Mass spectrometry (248) it will be of interest to explore the skeletal muscle proteome of mice 
who overexpress follistatin and identify the proteins that are up and down regulated in this model. 
Results from such experiments should provide additional targets to investigate in humans that may 
be involved in regulating muscle hypertrophy. 
The increased follistatin protein expression reported here is in contrast to a report of a study that 
investigated follistatin mRNA expression in the vastus lateralis of young males. This study reported  
no difference in expression after performing  an eccentric exercise protocol consisting of 6 sets of 
12-16 maximal single leg knee extensions on an isokinetic dynamometer at 60 ͦ/s (249). In the 
latter study, muscle biopsies were taken 11-15 days before the first exercise session and 24 h after 
the completion of the single bout of exercise. An additional study also investigated follistatin mRNA 
expression post performance of mainly sub-maximal (55%-75% 1-RM) concentric movements, 
consisting of both upper body (chest press, shoulder press and lateral pull down) and lower limbs 
movements (leg press variations). The results showed no significant difference in expression levels 
in muscle biopsies taken 9 h after post-exercise overnight recovery (250). These findings highlight 
the need to examine both mRNA and protein levels in order to obtain a more complete picture of 
how a gene functions in a physiological context. 
The upregulation of follistatin protein levels may be at least in part due to testosterone since the 
treatment of primary murine skeletal muscle cells with 100 nM of testosterone resulted in an 
increase in follistatin protein levels (251). Testosterone levels are increased as early as 15 min 
after exercise in humans consisting of either concentric or eccentric contractions performed during 
four different exercises: bench press, leg curls, leg extensions and military presses. During the 
eccentric exercise trial, the bars or machines were lifted and the subjects controlled the lowering of 
the weight, negative part of the motion (252). The study by Durand et al. (2013) therefore fit within 
the time frame for the increased follistatin protein expression at 4- and 24 h post plyometric 
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exercise. To assess for the possible role of testosterone in follistatin regulation after eccentric 
exercise, subjects who have low testosterone levels could be compared to those who have high 
testosterone levels. Furthermore, exercise studies could also be done to simply assess the 
correlation between testosterone and follistatin, which may suggest a connection between the two 
factors. If this was the case, it could stimulate more cell studies to reveal the mechanism for this 
association.   
The increase of IGF-1, and its isoforms (253,254) after exercise may also indirectly contribute to 
the increase in follistatin. This suggestion is based on information from studies on quail and duck, 
reporting that IGF-1 significantly increased the follistatin mRNA levels (209,210). When considering 
these reports, it could be suggested that the plyometric jumping (eccentric muscle contractions) 
stimulated the increase in IGF-1 which in turn significantly upregulated the expression of follistatin 
observed at 4 h and 24 h after exercise. However, future studies need to be done that also include 
analysis of circulating IGF-1 and muscle specific IGF-1, along with their isoforms, to validate our 
proposed suggestion.  
4.5 Decorin variants in human skeletal muscle 
 
Similar to follistatin, decorin has also been reported to be capable of binding myostatin (191) and 
hence may exert regulatory control over myostatin. There has been however no reported 
investigation of decorin expression in adult human skeletal muscle. Currently the main role 
ascribed to decorin in skeletal muscle is in fibrosis (255–257). Our findings therefore, with regards 
presence of two decorin splice variants termed here A1 and A2 in human skeletal muscle, are 
particularly noteworthy as presence of both of these transcripts has not been previously reported in 
the published literature. Both transcripts A1 and A2 are predicted to encode for the same decorin 
protein however their transcription initiation sites differ and hence suggest the existence of two 
different promoters for regulating decorin mRNA expression in adult human skeletal muscle in vivo. 
Such an occurrence likely results in different transcription factors being involved in the regulation of 
A1 and A2 transcription. Analysis of decorin mRNA expression using Taqman® probes that either 
detected both transcripts A1 and A2 or solely the A2 transcript did not demonstrate any significant 
changes in decorin expression at any of the time points analysed. At the time of doing these 
experiments there was not a commercially available Taqman® probe to measure solely the A1 
decorin transcript. It will be of future interest to develop such a probe as it will provide information 
on whether skeletal muscle preferentially upregulates either of these two decorin mRNA transcripts 
in response to eccentric training. Should a difference be observed in transcription of A1 and A2 it 
will then be of great interest to determine what transcription factors are involved in the regulating 
the differential expression.  
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4.6 Decorin protein analysis 
 
Similar to the investigation of decorin mRNA in adult human skeletal muscle no published literature 
was found in relation to decorin protein expression in adult human skeletal muscle. This is 
somewhat surprising, as decorin overexpression in C2C12 cells results in the creation of cells with 
greater hypertrophy than non-overexpressing cells (218). Furthermore decorin was also found to 
reduce the effects of exogenously applied myostatin to C2C12 cells (218) thereby supporting 
results from a previous study demonstrating an interaction between myostatin and decorin (191). 
In the present study decorin expression was initially investigated with a commercial antibody that 
was raised against a recombinant full length decorin protein however no signal was detected (data 
not showed). This lack of signal detection is not unusual as no enzyme was used to cleave any 
GAG chains attached to the core protein, which is the procedure in most studies investigating 
decorin with immunodetection (240–242).  Therefore protein lysates were subsequently treated 
with the enzyme chondroitinase ABC before blotting. The chondroitinase ABC enzyme is capable 
of degrading polysaccharides containing (1-4)-β-D-hexosaminyl and (1-3)-β-D-glucuronosyl or (1-
3)-α-L-iduronosyl linkages to disaccharides containing 4-deoxy-β-D-gluc-4-enuronosyl groups 
(Sigma datasheet). Western blot analysis of enzyme treated lysates with a commercial antibody 
directed towards the complete region of decorin core protein, resulted in the detection of two 
distinct immunoreactive proteins that migrated at approximately 38 kDa and 42 kDa. These 
proteins detected are in close size agreement with those detected by 40-42 kDa and with the 
predicted size of the decorin core protein. Additional antibodies directed towards different regions 
of decorin should be used to see if the same sized immunoreactive doublet is observed. 
Additionally for quantification purposes additional antibodies will hopefully give clearer images that 
can be used for quantification than those obtained here.  
Decorin is a widely expressed protein and hence it will also be of interest to determine whether the 
GAG chains differ between cell types. In the case of decorin, GAG chains are important for the 
organization of fibrils (258).The presence of GAG chains on decorin create an interesting issue 
with regards its detection in situations such as immunocytochemistry and immunohistochemistry. 
During the course of investigations for this thesis it was found that no decorin protein could be 
detected in protein lysates obtained from adult human skeletal muscle without prior treatment with 
the ABC chondroitinase enzyme. Hence investigations relating to the cellular localisation of decorin 
should also take heed of such findings as it may require pre enzyme treatment of tissue sections 
before staining otherwise an inaccurate profile of decorin cellular localisation may be obtained. The 
generation of antibodies that are capable of detecting decorin with its GAG chain still intact would 
be particularly useful in aiding the investigation of decorin in human skeletal muscle. 
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5 Chapter 5: Conclusion 
 
In conclusion, this study and thesis examined the effect of eccentric exercise, more specific 
plyometric jumping, on muscle damage and subsequently the response of the negative muscle 
regulator myostatin. Additionally factors that regulate myostatin’s action i.e. follistatin, Smad7 and 
decorin were also investigated. 
We show that the plyometric jumping protocol used in this study was adequate to produce muscle 
damage, resulting in increased circulating CK concentrations and reduced voluntary force 
production capabilities. The study also addressed factors affecting muscle regeneration, both 
positively and negatively. It was shown that this mode of eccentric exercise did not change protein 
levels of myostatin, it’s receptor (Activin IIb) and the status of downstream proteins Smad2/3 during 
the first 24 h post performance of the plyometric exercise. Furthermore, the concentration of 
inhibitory Smad7 also remained unchanged at all-time points. However, the protein concentration 
of follistatin showed significant increases post-eccentric exercise, making it one of the first studies 
using this protocol and reporting increased follistatin at protein level.  
Lastly, this study is the first investigation into human skeletal muscle revealing the existence of 
decorin splice variants; however no change in expression of these variants were observed in 
response to an acute bout of eccentric exercise. This is however a novel finding, opening the door 
to future research into decorin splice variants and their expression patterns in human skeletal 
muscle.  
5.1 Future research 
 
This study was one of the few which investigated factors capable of regulating myostatin, at protein 
level. However, this complicate matters when doing the research as the investigation of proteins 
with more affordable methods like immunoblotting, leads to difficulties as to finding correct 
antibodies which work with human samples and probe for the correct portion on the protein. In the 
case of proteins with multiple steps of processing, the variety of antibodies seems to be crucial. 
This calls for more companies to produce antibodies against several immunogens for the use in 
human muscle sample analysis. Furthermore, it is important for future studies investigating 
myostatin, to include quantification at several levels, i.e mRNA, precursor protein and mature 
dimer, combined with downstream activation in terms of Smad signalling activation and/or 
transcriptional gene targets (like p21). 
It has become clear that there are increasing amount of factors able to bind myostatin and thereby 
regulating its ability to bind to its designated receptor. Lately, more of the ECM proteins are being 
included in this group of regulators. Questions arise such as why these proteins bind myostatin, or 
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is it myostatin which binds them, thereby somehow changing their conformation and subsequently 
regulating their stability? These questions are also important in future research.  
Aside from myostatin, investigation into follistatin at a protein level is also highly recommended in 
all future studies which investigate myostatin and/or muscle regeneration. Follistatin is another 
protein which is post-translationally processed. This will need to be taken into account in future 
studies, possibly calling for immunoprecipation analyses to analyse the interaction between 
follistatin and myostatin in humans, in vivo. 
Decorin is becoming a very interesting highly important protein and myokine, investigated in 
several research areas from cancer and now skeletal muscle. The amount of functions attributed to 
this protein is astonishing and biochemical structural investigation may lead to clarifying which 
domains or amino acid sequence within the protein is responsible for functions. Cell models have 
demonstrated the effects of decorin on myotubes which calls for the change of model, maybe 
introducing over-expression of decorin in mice skeletal muscle. It would be very interesting to see 
the effect that overexpression of both follistatin and decorin has skeletal muscle in mice. These two 
factors together have the ability to regulate most, if not all, the factors which may negatively affect 
muscle growth. Decorin even goes further to control chronic or irregular fibrosis by binding to 
TGFβ-1. I would include these factors in models investigating muscle dystrophy.  
When investigating human skeletal muscle, it would be strongly suggested to continue with our 
research into the genetic regulation of decorin to further investigate the newly discovered A1 and 
A2 variants in human skeletal muscle. This calls for analysis into the transcriptional factors 
involved in their expression, which will subsequently aid in clarifying the stimulus involved in their 
expression. The investigation into other variants may also be useful, as there are presently several 
variants listed on the NCBI database. Downstream of the mRNA, the decorin protein is also crucial 
and we call for the use of 2 or more antibodies in future studies, after treatment with chondroitinase 
ABC. This will allow the accurate identification and quantification of the 359 aa (40-42 kDa) decorin 
protein in human skeletal muscle, as the possibility of decorin isoforms or degraded decorin is 
promising and realistic. The future research for decorin in human skeletal muscle may be 
challenging, but taking into account its variety of functions and its potential as a muscle mass 
regulator, it would be almost absurd not to continue with this research pertaining to decorin. 
Techniques / Methods  
Further suggestions concerning techniques would be that future studies also make use of different 
methods to clarify several questions raised concerning, but not limited to, the different forms of 
proteins and possible isoforms. One of the most effective methods for this suggestion would be 
mass spectrometry (MS). This allows the investigation of several proteins at once, by cutting out a 
complete lane in the SDS-PAGE gel. Apart from identifying the proteins, the MS could be 
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connected to analysers which are able to also sequence these proteins. This would aid in 
characterizing the possible isoforms of the proteins by amino acid sequence and use online 
database to identify sequences present in other proteins which may clarify the function of these 
isoforms. It would suggested that MS be used in both serum and muscle samples where possible.  
The use of MS with RT-PCR is the future for research; however, the financial implications 
associated with these techniques may still be too high to introduce to regular studies. 
Exercise protocols 
In the present study, we used the plyometric protocol which is regularly used within our 
department. This is effective for the investigation of eccentric exercise on muscle damage and 
repair, however, all the different research groups seems to have their own protocols. This makes it 
difficult to compare results between studies. I would therefore suggest that international research 
group clusters are formed, in which the labs use the same protocol with similar subjects (in terms 
of characteristics) to evaluate or investigate a factor. By this I mean that if several labs with 
different specialities are able to work together, it will save time and enable research questions to 
be answered in full and in a shorter amount of time. In this way it would be able to conclude all 
different aspects of say plyometric jumping on muscle damage, repair and/or adaptations while 
looking at a variety of factors at once. This would allow studies to also be compared to each other.  
On the topic of exercise protocol, I would strongly suggest a change in regular use protocols to 
exercise regimes closer to those used by athletes in present times. In the athlete arena, training 
regimes are changed regularly while science are somewhat lagging behind. This makes it difficult 
for athletes to use information from scientific studies as this is not always accurate when compared 
to how they are training. 
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6 Appendices 
 
Advertisement poster 
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Informed consent 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
 
Myostatin: roles in skeletal muscle structure, regulation and regeneration after eccentric exercise 
REFERENCE NUMBER:N12/08/051 
PRINCIPAL INVESTIGATOR: Prof. K.H. Myburgh 
ADDRESS: Department of Physiological Sciences 
 c/o Merriman &Bosman Road 
 Mike de Vries Building 
 Stellenbosch University 
 Stellenbosch 
 7600 
 
CONTACT NUMBER:  021 808 3149 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you could be involved.  Also, your participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
 This study will be performed at the Department of Physiological Sciences of the University 
of Stellenbosch. 
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This study will be focusing on the healing process of skeletal muscle after micro-damage induced 
by exercise of a type that includes a lengthening contraction. This process is influenced by several 
factors able to control or affect muscle in a negative or positive way. The muscular influential 
factors are crucial for determining muscle mass, particularly after micro-damage. Research results 
don’t present a clear picture, but most provided results showing that a factor that limits muscle 
growth (myostatin) is increased at the beginning of injury, despite the fact that new muscle must be 
formed.  
This study aims to focus on why this myostatin factor plays a role after micro-damage. The study 
will also be focusing on factors that are studied less than myostatin that are able to bind and 
reduce the anti-growth effects of myostatin. 
 
The results may 1) indicate if myostatin plays a role in muscle regeneration 2) identify possible 
factors able to control the effects of myostatin during muscle regeneration. 
What will be done? 
The study will be conducted in the Exercise physiology laboratory at the Mike de Vries building, 
(Department of Physiological sciences), Stellenbosch University. We plan to do the actual study 
using a total of 16 participants (n=16). 
 
Before the start of the actual study, you will be asked to participate in a screening process. This will 
consist out of a fitness test and a strength analysis test. All the tests will be performed in-house. 
The participants will be divided into 3 groups (A,B,C) of 10 for the screening process. The study 
will start with a blood draw (baseline) and a week later the fitness tests will start. After the holiday, 
the first muscle biopsy (baseline) will be taken and followed by 1stround of strength tests. (The 
strength tests will be one week from each other).  
At this time, we will have collected enough information to conclude which participants will be suited 
for the study. These 16 participants will continue to the exercise protocol and post-exercise muscle 
biopsies and blood draws. 
Fitness test: Cycling VO2 max test - You will be cycling for one minute periods at an increasingly 
higher resistance until they can no longer pedal. The subject’s peak oxygen consumption rate and 
peak cycling wattage will be measured and recorded. In order to assess oxygen consumption rate, 
you will be required to perform the test with a mask placed over their mouth and nose. Subjects will 
be able to easily inhale room air while expired air will be analyzed for oxygen and carbon dioxide 
content.  
Strength test – A quadriceps isometric force test on a leg extension apparatus set at 70°.You will 
have 3 attempts to produce your maximum force. The average force of the 3 attempts will be used 
as your result.  
 
You will be expected to come in to the laboratory 9 times on 8 different days 
(A detailed calendar time line is attached, please see pages at the end) 
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During these visits, the following will happen: 
 
Visit 1 (Blood baseline): First, you will be requested to sign the informed consent form.  
Then we will perform baseline measurements – weight, height and blood pressure 
Baseline blood draw will be collected 
Visit 2 (Fitness test): You will perform your fitness, VO2max test 
Visit 3 (Muscle Biopsy Baseline): This will be the first visit where a muscle biopsy will be taken 
from your vastus lateralis (upper leg) 
Visit 4 (Strength/Force test): First round of strength tests 
Visit 5 (Strength/Force test): Second round of your strength tests 
Visit 6 (Exercise protocol): You will be asked to perform the plyometric exercise protocol 
(Verticalexplosive jumps):10-minute warm-up and stretching will be followed by the exercise 
intervention.  
The plyometric regime will consist of 10 sets of 10 repetitions (90% of your maximum height) 
Leg circumference and blood draws will be taken prior to jumping  
Visit 7 (4 Hours post-exercise): Leg circumference, blood sample and muscle biopsy 
Visit 8 (24 hours post-exercise): Leg circumference, blood sample and muscle biopsy (opposite 
leg) 
Visit 9 (48 hours post-exercise): This will be the 5th and final blood draw and also the post-
exercise force production test 
Plyometric Exercise Regimen:  
 
Prior to the start of the exercise regime, you will be handed a piece of chalk to use as a marker for 
your three maximal jump attempts. The height of the three chalk marks will be measured from the 
ground and the average calculated. The height that represents 90% of your maximum jumps height 
will then be indicated by a strip of tape and this will serve as your target height for each jump. Each 
jump that does not reach this height, will be counted and you will be asked to perform the 
additional jumps at the end of the protocol to conclude 100 jumps of 90% of your maximum jump 
height. 
 
To induce micro-muscle damage, you will be asked to perform ten sets of ten maximal vertical 
jumps. The sets will be separated with a 60 second recovery period. On landing of each jump, you 
Stellenbosch University  http://scholar.sun.ac.za
72 
 
Copyright © 2014 Stellenbosch University   All rights reserved  
 
will be instructed to adopt a knee joint angle of approximately 90° in order to promote muscle 
damage as described in scientific literature. This plyometric exercise protocol will induce non-
severe muscle damage, which will not reduce your mobility after the protocol is done. 
There will be an individual given the task to observe your jumps and to confirm that your finger tips 
reach your target line. 
 
Muscle biopsies: 
 
Muscle biopsies will be performed by a medical doctor (Dr. J. Brink) using local skin anaesthesia, 
open surgical biopsies from the thigh muscle will be obtained on different days as described above 
(see calendar). The first muscle biopsy will be performed on a random leg and the following biopsy 
on the opposite leg, as this will help to reduce any possible differences between the dominant/non-
dominant legs. During the procedure a piece of approximately 50-100mg of muscle will be taken. 
This is a relatively small amount, almost the size of the tip of a ballpoint pen. This procedure will 
not have a negative influence on your muscle function and your muscle will recover completely 
within a short period of time. Although, pain may be present at the biopsy site during sports 
participation for a period of 1-2 days, it is not sufficient to limit sports participation in non-contact 
sport. You should refrain from sporting activity for 1 day after a biopsy, but are free to recommence 
participation on day 2 after a biopsy.    
 
Blood collection:  
 
All blood samples will be drawn from the forearm by a qualified phlebotomist (trained and certified 
to draw blood) using a double sided needle and a standard serum separating tube (SST) 
At each time point, 10ml (one teaspoon) of blood will be drawn. A total of 50ml of blood will be 
drawn throughout the study. 
 
Why have you been invited to participate? 
You are invited to participate in this study because your physical characteristics fit with the 
expected criteria needed for this study and were selected through the strength and fitness 
screening process.  
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What will your responsibilities be? 
You will be expected to participate in study by doing the activities described above for visits 1-9. 
Your participation is entirely voluntary and you are free to decline participation or withdraw from the 
study at any time.  If you choose to say “no” or withdraw, this will have no consequences for you, in 
any way.   *Any further questions that you may have relating to the experiment will be answered in 
full by the co-ordinator: Prof K.H. Myburgh (021 808 3149). 
 
Will you benefit from taking part in this research? 
You will have no personal benefits from taking part in this study. 
 
Are there in risks involved in your taking part in this research? 
 The risks of having blood drawn and muscle biopsies include soreness, bruising at the 
puncture site and risk of infection. They will be minimized using sterilized equipment and an 
anesthetic drug only during muscle biopsies. All the procedures will be done by experienced 
personnel with sufficient relevant training. The amount of blood and muscle to be taken is not 
considered to be a significant amount, and is therefore not expected to have any significant risk for 
you. 
 
The risks of having plyometric exercise intervention include delayed muscle soreness and possible 
low-risk injury. We will however insure that you will warm-up adequately and that you as 
participants understand the correct form of the exercise to decrease the possibility of injuries. 
However, should you require medical care as a result of negligence in this study, it will be made 
available free of charge. 
If you experience any pain or discomfort as a result of your participation, please contact the 
principal investigator, at the number provided at the top of this form. 
 
If you do not agree to take part, what alternatives do you have? 
Your participation is entirely voluntary and you are free to decline to participate.  If you say no, this 
will not affect you negatively in any way whatsoever. 
 
Who will have access to your medical records? 
All information will be kept strictly confidential. Experimentation will not commence without your 
consent. Your identity will remain anonymous.  Only Prof K.H. Myburgh and Mr J.D. Conradie will 
have access to your personal information and to your experimental data. The Research Ethics 
Committee members, who approved this study, will also have the right to inspect research records. 
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What will happen in the unlikely event of some form of injury occurring as a direct result of your 
taking part in this research study? 
In the unlikely event that you sustained some form of injury as a result of your participation due to 
negligence on our side, the University has insurance to cover medical expenses. 
Will you be paid to take part in this study and are there any costs involved? 
 
You will be compensated pro rata for your time and any inconvenience for participating in the 
study, but if you withdraw from the study at any point after you agreed to participate you will only 
be compensated for the part that you did participate in. There will be no additional costs involved 
for you, if you do take part. *if you do not proceed past the screening process, we will still 
compensate you for your troubles up to the point where you participated in the study 
 
Is there anything else that you should know or do? 
You can contact Prof K.H Myburgh at tel: 021 808 3149 if you have any further queries or 
encounter any problems. 
You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own records. 
The researchers involved in this study have no financial or non-financial interests, which 
may inappropriately influence us in the conduct of this research study.  
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled (insert title of study). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2013. 
 
 
 
 ...................................................................  ................................................................. 
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use a interpreter.   
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2013. 
 
 
 
 ...................................................................  ................................................................. 
Signature of investigator Signature of witness 
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Question form 
 
 Principal Investigator: Prof. K.H Myburgh 
  Sub-investigator: J.D Conradie 
Myostatin: roles in skeletal muscle structure, regulation and regeneration after eccentric 
exercise 
Name:    Surname:     US Number: 
Cell no:    Age:   Height:   Weight: 
 
Physical activity and Injury questionnaire: 
Physical Activity: 
Do you, or did you participating in any competitive sport at university?  
If yes, what sport did/are you participating in? 
 ………………………………………………………… 
How long ago?  
currently: <2 months ago:  2 months ago:  6 months ago:  1 year 
ago:   > 1 year ago:   
Do you currently participate in any recreational physical activity? 
If yes, what?  ……………………………………………………….. 
How often? 
 < twice a week  twice a week  3 times a week  > 3 times 
a week 
In the past 4 weeks? 
< twice a week  twice a week  3 times a week  > 3 times 
a week 
At what intensity?     
  Low:   moderate:  high: 
Do the activities include any eccentric exercises?   
 
 
N Y 
    
 
Y N 
    
    
   
Y N 
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What is your current level of fitness? 
  Unfit:   Moderately fit:  Highly trained: 
Injury history: 
Have you had any injury to your lower extremities? 
If yes, where? 
  Hip:  knee:  Ankle:  upper leg:  lower leg:  
Of what nature? 
  Sprain:  Strain:  Contusion:        injury to bone:   
  Dislocation: 
How long ago? 
  < 2 months ago: 3 months ago:  6 months ago:  1 year ago: 
> 1 year ago: 
 
Are you currently using any medication or supplementation?  
If yes, please specify   ……………………………………. 
 
Are you currently on any diet restrictions etc?      
If yes, please be specific as to what it attain to ……………………….. 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
Y N 
  
 
    
    
 
Y N 
Y N 
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Subject details at the time of the trials 
Name, Surname Code Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
VO2max  
(ml/kg/min) 
JT Motto-Ros JTMR 21 179.1 73.6 43.46 
Timothy van Niekerk TvN  20 174.00 70.2 47.9 
Julian Wissing JW 19 179.70 84.2 47 
Wesley van der Westhuizen WvdW 19 181.60 74 50.5 
Adarsh Shah AS 20 178.10 58.4 43.6 
WG Klingenberg WGK 25 177.6 105.2 38.4 
Pieter-Simon Basson PSB 23 185.1 73.2 42.14 
Cloete du Preez CdP 22 180 84.6 43.62 
Matthew Bergsteedt MB 20 173.4 68.8 42.6 
Ruan Aucamp RA 19 181.4 84.2 45.3 
Charl Engels CE 28 186 113.2 38.16 
MP Austin MPA 20 178.5 73.6 55.7 
Bradwill Markgraaf BM 20 178 55 45.08 
Tope Ogundipe TO 20 177 73 44.4 
Claus van Wyk CvW 19 178 63.8 44.1 
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Individual creatine kinase values (u/L) 
Name, Surname Code Baseline 
1 
Baseline 2 4 hours 
Post 
24 hours  
Post 
48 hours 
post 
JT Motto-Ros JTMR 151 177 164 2390 4980 
Timothy van Niekerk TvN  125 87 106 120 135 
Julian Wissing JW 269 244 256.5 319 618 
Wesley van der Westhuizen WvdW 200 238 219 257 389 
Adarsh Shah AS 162 309 235.5 352 432 
WG Klingenberg WGK 142 115 128.5 180 373 
Pieter-Simon Basson PSB 172 143 157.5 230 518 
Cloete du Preez CdP 123 192 157.5 564 709 
Matthew Bergsteedt MB 100 92 96 543 768 
Ruan Aucamp RA 231 191 211 1776 2167 
Charl Engels CE 120 128 124 351 701 
MP Austin MPA 310 187 248.5 223 346 
Bradwill Markgraaf BM 134 145 139.5 161 370 
Tope Ogundipe TO 455 634 544.5 625 703 
Claus van Wyk CvW 95 106 100.5 419 624 
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Individual isometric force production values (N/kg) 
Name, Surname Baseline 
1 
Baseline 2 Highest 
baselin
e 
Immediately 
Post 
1 week post 
JT Motto-Ros 15.24 16.223 16.223 10.901 15.652 
Timothy van Niekerk 8.48 8.476 8.48 12.422 12.607 
Julian Wissing 11.75 16.591 16.591 13.480 15.499 
Wesley van der Westhuizen 11.98 14.311 14.311 13.446 15.162 
Adarsh Shah 10.94 14.207 14.207 9.298 10.548 
WG Klingenberg 10.97 10.124 10.97 9.905 10.371 
Pieter-Simon Basson 12.87 11.503 12.87 10.656 10.888 
Cloete du Preez 11.67 12.621 12.621 11.749 11.678 
Matthew Bergsteedt 7.94 9.172 9.172 9.724 11.003 
Ruan Aucamp 11.64 12.553 12.553 13.005 15.724 
Charl Engels 11.79 11.446 11.79 11.696 14.055 
MP Austin 11.43 16.386 16.386 14.348 15.285 
Bradwill Markgraaf 14.22 14.285 14.285 14.764 14.655 
Tope Ogundipe 10.65 11.082 11.082 11.247 11.178 
Claus van Wyk 14.11 14.592 14.592 13.683 16.332 
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RNA analysis – detailed information 
Code Time point RNA concentration Decorin 2200 
expression 
Decorin 5781 
expression 
BM Baseline  1.061 3.317 
 4 hours post   0.597 1.495 
 24 hours post  0.853 2.585 
WGK Baseline  0.886 1.597 
 4 hours post   0.880 0.963 
 24 hours post  0.570 2.049 
CE Baseline  
Outlier values 
1.945 
 4 hours post   2.639 
 24 hours post  2.540 
CdP Baseline  0.740 1.380 
 4 hours post   0.705 1.959 
 24 hours post  3.171 2.227 
WvdW Baseline  1.320 1.664 
 4 hours post   0.511 2.021 
 24 hours post  0.693 2.354 
 
Antibody information 
 
Activin receptor IIb 
 Manufacturer: Abcam (anti-activin receptor IIB ab10596) 
 Specie: goat polyclonal 
 Isotype: IgG 
 Immunogen: recombinant fragment (human) 
 Specie specificity: human 
 Datasheet:http://www.abcam.com/Activin-Receptor-TypeIIB-antibody-ab10596.thml 
 
Smad6/7 
 Manufacturer: Santa Cruz Biotechnology (Smad6/7 (N-19): sc-7004) 
 Specie: Goat polyclonal 
 Isotype: IgG 
 Immunogen: N-terminal 
 Specie specificity: mouse, rat and human 
 Datasheet: http://www.scbt.com/datasheet-7004-smad6-7-n-19-antibody.html 
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Smad 2/3-p 
 Manufacturer: Santa Cruz Biotechnology (p-Smad2/3 (Ser 423/425): sc-11769) 
 Specie:rabbit polyclonal 
 Isotype:IgG 
 Immunogen: phosphorylatedSer 423 and Ser425 
 Specie specificity: mouse, rate and human 
 Datasheet: http://www.scbt.com/datasheet-11769-p-smad2-3-ser-423-425-antibody.html 
Decorin 
 Manufacturer: Abcam (Anti-decorin: ab54728) 
 Specie: mouse monoclonal 
 Isotype: IgG2b 
 Immunogen: 1-360 aa human decorin  
 Specie specificity: human and recombinant fragment 
 Datasheet: http://www.abcam.com/decorin-antibody-ab54728.html 
 
Myostatin 
 Manufacturer: Abcam (anti-GDF-8: ab98337) 
 Specie: rabbit polyclonal 
 Isotype: IgG 
 Immunogen: aa 300 – C-terminal 
 Specie specificity: mouse, horse, chicken and human 
 Datasheet: http://www.abcam.com/gdf8--myostatin-antibody-ab98337.html 
 
Follistatin 
 Manufacturer: Abcam (anti-follistatin: ab47941) 
 Specie: rabbit polyclonal 
 Isotype: IgG 
 Immunogen: full length human follistatin 
 Specie specificity: human 
 Datasheet: http://www.abcam.com/follistatin-antibody-ab47941.html 
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